ARYL substituent-containing degradation agent for CDK12 / 13, preparation method therefor, and pharmaceutical composition and use thereof
Patent Information
- Application Number
- MYPI2025005164
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-24
- Filing Date
- 2024-02-22
- Publication Date
- 2024-08-24
AI Technical Summary
Existing CDK12/13 kinase inhibitors cannot effectively inhibit the non-kinase functions of CDK12/13, leading to low efficacy and drug resistance problems, and simply inhibiting kinase activity is not enough to completely inhibit its role in tumors.
A type of trans-1,4-cyclohexanediamine compounds were developed as CDK12/13 degraders. They induce the degradation of CDK12/13 proteins through the PROTAC principle and achieve comprehensive inhibition of CDK12/13 kinase and non-kinase functions.
The compound can highly selectively degrade CDK12/13 protein kinase and inhibit the proliferation, migration and invasion of various tumor cells, providing more potent therapeutic potential.
Smart Images

Figure PI2025005164_DRAWING_001 
Figure PI2025005164_DRAWING_002 
Figure PI2025005164_DRAWING_003
Abstract
Description
A class of degraders containing aromatic-substituted CDK12 / 13, as well as preparation methods, pharmaceutical compositions and applications thereof Technical Field
[0001] The present invention belongs to the field of chemical medicine, and in particular relates to a degrader of cell cycle-dependent protein kinase 12 / 13 (CDK12 / 13), a pharmaceutical composition thereof, and an application thereof. Background Art
[0002] Protein kinases are key regulators of cellular function, constituting one of the largest and most diverse gene families. Protein kinases direct the activity, localization, and overall function of many proteins through phosphorylation of substrate proteins and are involved in almost all cellular activities. Abnormalities in the expression, activation, and localization of protein kinases are closely related to the occurrence and development of a variety of diseases and are important driving factors for a variety of diseases such as tumors and inflammation. As of December 31, 2020, the FDA has approved a total of 62 kinase inhibitor drugs for marketing. Studies have found that the non-kinase functions of proteins play an important role in diseases such as tumors. The literature has reported the non-kinase functions of kinases such as CDK6, FAK, EGFR, PIPK3, PDK1, BRAF, CRAF, CHK2, ZAP70, AKT, and Aurora A. Therefore, simply inhibiting the activity of kinases cannot completely inhibit the non-kinase functions of kinases, resulting in potential adverse effects such as low efficacy and drug resistance. Therefore, the development of protein degraders is expected to comprehensively inhibit the enzymatic activity and non-kinase functions of kinases, exerting a potent therapeutic effect. Protein degraders based on the PROTAC principle are currently the most successful and mature protein degradation strategy, and have been successfully used in the development of degraders for multiple kinases and other targets.
[0003] PROTACs refer to a class of small molecules that can specifically recognize and induce the degradation of target proteins. Their molecular structure consists of a target protein recognition ligand, a linker, and an E3 recognition ligand. The advantages of PROTACs are that they not only effectively inhibit the kinase activity of the target protein but also rapidly degrade and eliminate it. In theory, only a catalytic amount of drug is needed to degrade nearly all proteins in the cell (including membrane proteins), resulting in high safety, drug resistance, and broad application prospects. Degraders targeting target proteins such as ERR, ABL, BET, and CDK4 / 6 have been successfully developed, demonstrating their potential to treat the proliferation of genetically driven tumors and overcome inhibitor resistance. In 2018, Pfizer announced an $830 million investment in the development of protein degraders based on PROTAC technology. In March 2019, WuXi AppTec's partner, Arinas, announced that its androgen receptor-targeting protein degrader, ARV-110, had entered clinical trials; this was the world's first protein degrader to enter clinical trials.
[0004] CDK12 / 13 (Cyclin-dependent kinase 12 / 13) are members of the cyclin-dependent kinase family (CDKs) of serine / threonine protein kinases. They form a complex with cyclin K to exert their biological functions. CDK12 / 13 contain 1490 and 1512 amino acids, respectively, and share 46% homology. The kinase domain, consisting of 300 amino acids, has a high homology of 92%. CDK12 / 13 form a complex with cyclin K by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNA Pol II). The CTD consists of a highly repetitive sequence of seven amino acids, YSPTSPS. In humans, the CTD consists of 52 repeats. CDK12 / 13 primarily phosphorylates Ser2, thereby regulating transcription and post-transcriptional mRNA processing. Genetic studies have shown that CDK12 promotes full-length gene transcription by inhibiting the cleavage of intronic polyadenylation sites. Many homologous recombination repair genes (e.g., BRCA1 / 2, ATM, ATR, FANCD2, FANCI, etc.) contain more intronic polyadenylation sites, making their expression more sensitive to CDK12 loss or inhibition. Compared to other transcriptional CDKs, CDK12 / 13 contain an additional arginine / serine-rich (RS) motif at their N-termini. RS motifs are commonly found in proteins involved in pre-mRNA splicing. Proline-rich motifs (PRIM) motifs are also found at the N- and C-termini, potentially serving as binding sites for proteins containing SH3, WW, or actin-binding protein (profilin) domains. These structures suggest that CDK12 / 13 may have non-kinase functions (e.g., protein-protein interactions) that play a crucial role in mRNA splicing and mRNA 3' end processing. Therefore, using only CDK12 / 13 kinase inhibitors as probes for studying the biological functions of CDK12 / 13 is insufficient. The use of proteolysis-targeting chimeras (PROTACs) to induce CDK12 / 13 degradation while simultaneously inhibiting both kinase and non-kinase functions has great potential for studying the biological functions of CDK12 / 13 and treating diseases, and has attracted increasing interest among scientists in recent years.
[0005] Summary of the Invention
[0006] Based on this, the present invention provides a class of trans-1,4-cyclohexanediamine compounds and their use as CDK12 / 13 degraders. These compounds can effectively and highly selectively degrade CDK12 / 13 protein kinases and inhibit the proliferation, migration and invasion of various tumor cells.
[0007] In the first aspect of the present invention, there is provided a compound having a structure of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof or a prodrug molecule thereof:
[0008] Wherein, Z is CH2 or CO;
[0009] V is selected from the following group:
[0010] X and Y are each independently selected from the group consisting of N, CH, or CR3; wherein R3 is selected from the group consisting of halogen, cyano, hydroxy, amino, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, halogenated C1-C3 alkoxy, C3-C8 cycloalkyl, or 3-8 membered heterocyclyl;
[0011] B is selected from the following group: NH, O, CO, CH2; wherein each U and W are independently selected from the following group: N or CH; each m, p, m', p' are independently: 0, 1, 2 or 3;
[0012] Ring A is selected from the group consisting of:
[0013] Wherein, Q and W are each independently selected from: CH, N;
[0014] R' is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, substituted hydroxy, amino, substituted amino, C1-C5 alkyl, halogenated C1-C5 alkyl, C1-C5 alkoxy, halogenated C1-C5 alkoxy, C3-C8 cycloalkyl, and when Q and W are independently selected from CH, R' may be a substituent on Q and W;
[0015] D, E, F, and G are each independently selected from the group consisting of CH, N, and CR6; wherein R6 is selected from the group consisting of halogen, trifluoromethyl, hydroxy, cyano, amino, methyl, methoxy, and trifluoromethoxy;
[0016] R1 is selected from the group consisting of H, -NHR7, -OR7, -(C(R9)R8)R7;
[0017] Among them, R7 is -R 10 、-CH2R 10 or -(CH2)2R 10 ;
[0018] R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, cyano, methyl, halomethyl, methoxy, halomethoxy, ethyl, haloethyl, ethoxy, haloethoxy, hydroxy, amino, and a 3-8 membered heterocycle containing 1, 2 or 3 heteroatoms selected from O, S or N;
[0019] Or R8, R9 and the C atoms to which they are connected together form a 3-7 heterocyclic ring;
[0020] R 10 Select from the following groups:
[0021] 1) Cyano, C1-C5 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, C3-C 10 Cycloalkyl, substituted or unsubstituted 5-12 membered aromatic ring, substituted or unsubstituted 3-12 membered heterocyclic ring;
[0022] 2)
[0023] wherein Q1, Q2, Q3, Q4, and Q5 are each independently selected from: CH, N, or CR 11 ;
[0024] Each R 11 Each is independently selected from the group consisting of halogen, cyano, hydroxy, amino, nitro, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, C3-C8 cycloalkyl;
[0025] R2 is selected from the following group: H, C1-C3 alkyl,
[0026] When B is selected from the following group: NH, O, CO, CH2; wherein each U and W are independently selected from the following group: N or CH; each m, p, m', p' are independently: 0, 1, 2 or 3;
[0027] Linker is:
[0028] in,
[0029] R L1 、R L2 、R L3 、R L4 and R L5 are the same or different and are each independently selected from the following groups, substituted or unsubstituted: chemical bond, CH2, CHD, CD2, C=O, O, NH, SO, SO2, P=O, NHCO, NHSO2, OCH2, OCH2CH2, CH2OCH2, NHCH2, NMeCH2, NHCH2CH2, NMeCH2CH2, CH2NHCO, NHCOCH2,
[0030] R L6 is a ring, and is optionally selected from the following structures:
[0031] wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m are independently 0, 1 or 2; each U and W are independently selected from the group consisting of N or CH
[0032] p L1 、p L2 、p L3 、p L4 、p L5 and p L6 Independently selected from 0, 1, 2, 3, 4, 5, or 6.
[0033] When B is Wherein each m, p, m', p' is independently: 0, 1, 2 or 3;
[0034] Linker is:
[0035] in,
[0036] R L1 、R L2 、R L3 、R L4 、R L5 and R L6 are the same or different and are each independently selected from the following groups, substituted or unsubstituted: chemical bond, CH2, CHD, CD2, C=O, O, NH, SO, SO2, P=O, NHCO, NHSO2, OCH2, OCH2CH2, CH2OCH2, NHCH2, NMeCH2, NHCH2CH2, NMeCH2CH2, CH2NHCO, NHCOCH2,
[0037] wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m are independently 0, 1 or 2; each U and W are independently selected from the group consisting of N or CH;
[0038] p L1 、p L2 、p L3 、p L4 、p L5 and p L6 Independently selected from 0, 1, 2, 3, 4, 5, or 6.
[0039] In some embodiments, V is selected from the group consisting of:
[0040] In some embodiments, X and Y are each independently selected from the group consisting of N, CH or CR3;
[0041] Wherein, R3 is selected from the following group: halogen, cyano, hydroxyl, amino, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, halogenated C1-C3 alkoxy.
[0042] In some embodiments, B is selected from the group consisting of: NH, O, CO;
[0043] wherein each U and W are independently selected from the group consisting of N or CH; and each m, p, m', and p' are independently 0, 1, 2, or 3.
[0044] In some embodiments, Ring A is selected from:
[0045] Wherein, W is selected from the following group: CH, N.
[0046] R' can be selected from: hydrogen, halogen, cyano, hydroxy, amino, C1-C5 alkyl, halogenated C1-C5 alkyl, C1-C5 alkoxy, halogenated C1-C5 alkoxy, C3-C8 cycloalkyl
[0047] In some embodiments, D, E, F, and G are CH and CR6; wherein R6 is selected from the following group: halogen.
[0048] In some embodiments, the R1 is -NHR7;
[0049] Wherein, R7 is -CH2R 10 ; R 10 The definition of is as mentioned above.
[0050] In another preferred embodiment, the R 10 Selected from the following groups: cyano, C1-C5 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, C3-C 10 Cycloalkyl, 4-7 membered heterocyclic group, C6-C 10 Aryl; wherein the aryl is replaced by one or more CR 11 Replacement; R 11 The definition of is as mentioned above.
[0051] In some embodiments,
[0052] When B is selected from the following group: NH, O, CO;
[0053] When, the Linker is selected from the following group:
[0054] And when B is When the linker is selected from the following group: chemical bond, wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m is independently 0, 1 or 2; and each U and W is independently selected from the group consisting of N or CH.
[0055] In some embodiments, the compound has a structure shown in formula (II):
[0056] Wherein, B is selected from: wherein each U and W are independently selected from the group consisting of N or CH; each m, p, m', p' are independently 0, 1, 2 or 3;
[0057] R' is optionally selected from: hydrogen, halogen, cyano, hydroxyl, amino;
[0058] R 11 , R6 is optionally selected from: hydrogen, halogen;
[0059] X, Y are independently selected from: CH, N or CR3; wherein R3 is selected from: halogen, cyano, hydroxyl, amino;
[0060] Z is selected from: CH2 or CO;
[0061] In some embodiments, the compound is selected from the group consisting of:
[0062] In a second aspect of the present invention, a compound having a structure of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, or a prodrug molecule thereof is provided:
[0063] wherein Z is selected from the group consisting of CH2 or CO;
[0064] V is selected from the following group:
[0065] X and Y are selected from the group consisting of N, CH, or CR3; wherein R3 is selected from the group consisting of halogen, cyano, hydroxy, amino, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, halogenated C1-C3 alkoxy, C3-C8 cycloalkyl, or 3-8 membered heterocyclyl;
[0066] B is selected from the following group: NH, O, CO, CH2; wherein each U and W are independently selected from the following group: N or CH; each m and p are independently: 0, 1 or 2;
[0067] Ring A is selected from the group consisting of:
[0068] M and T are each independently selected from the following group: N, CR4;
[0069] I, J, K are each independently selected from the group consisting of N, O, S, CR4, and NR4;
[0070] R4 is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, amino, C1-C5 alkyl, halo-C1-C5 alkyl, C1-C5 alkoxy, halo-C1-C5 alkoxy, C3-C8 cycloalkyl, -CH2R5, -(CH2)2R5, -(CH2)3R5, or 3-8 membered heterocyclyl;
[0071] R5 is selected from the group consisting of cyano, hydroxy, amino, C3-C8 cycloalkyl, or 3-8 membered heterocyclyl;
[0072] D, E, F, and G are each independently selected from the group consisting of CH, N, and CR6; wherein R6 is selected from the group consisting of halogen, trifluoromethyl, hydroxy, cyano, amino, methyl, methoxy, and trifluoromethoxy;
[0073] R1 is selected from the group consisting of H, -NHR7, -OR7, -(C(R9)R8)R7;
[0074] Among them, R7 is -R 10 、-CH2R 10 or -(CH2)2R 10 ;
[0075] R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, cyano, methyl, halomethyl, methoxy, halomethoxy, ethyl, haloethyl, ethoxy, haloethoxy, hydroxy, amino, and a 3-8 membered heterocycle containing 1, 2 or 3 heteroatoms selected from O, S or N;
[0076] Or R8, R9 and the C atoms to which they are connected together form a 3-7 heterocyclic ring;
[0077] R 10 Select from the following groups:
[0078] 1) Cyano, C1-C5 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, C3-C 10Cycloalkyl, substituted or unsubstituted 5-12 membered aromatic ring, substituted or unsubstituted 3-12 membered heterocyclic ring;
[0079] 2)
[0080] wherein Q1, Q2, Q3, Q4, and Q5 are each independently selected from: CH, N, or CR 11 ;
[0081] Each R 11 Each is independently selected from the group consisting of halogen, cyano, hydroxy, amino, nitro, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, C3-C8 cycloalkyl;
[0082] R2 is selected from the following group: H, C1-C3 alkyl,
[0083] Linker is:
[0084] Among them, R L1 -R L6 are the same or different and are each independently selected from the following groups, substituted or unsubstituted: bond, CH2, CHD, CD2, C=O, O, NH, SO, SO2, P=O, NHCO, NHSO2, OCH2, OCH2CH2, CH2OCH2, NHCH2, NMeCH2, NHCH2CH2, NMeCH2CH2, CH2NHCO, NHCOCH2,
[0085] wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m are independently 0, 1 or 2; each U and W are independently selected from the group consisting of N or CH
[0086] The substitution refers to substitution by one or more groups selected from the group consisting of hydrogen, deuterium, C1-C 18 Alkyl, deuterated C1-C 18 Alkyl, halogenated C1-C 18 Alkyl, halogenated C1-C 18 Alkyl hydroxyl, C3-C 20 Cycloalkyl, C1-C 18 Alkoxy, deuterated C1-C 18 Alkoxy, halogenated C1-C 18 Alkoxy, C6-C 14aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclic group, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide or urea;
[0087] Each p L1 -p L6 Independently selected from 0, 1, 2, 3, 4, 5, or 6.
[0088] In some embodiments, V is selected from the group consisting of:
[0089] In some embodiments, X and Y are each independently selected from the group consisting of N, CH or CR3;
[0090] Wherein, R3 is selected from the following group: halogen, cyano, hydroxyl, amino, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, halogenated C1-C3 alkoxy.
[0091] In some embodiments, B is selected from the group consisting of: NH, O, CO;
[0092] wherein each U and W are independently selected from the following group: N or CH; and each m and p are independently 0 or 1.
[0093] In some embodiments, Ring A is selected from the group consisting of:
[0094] Wherein, T is selected from the following group: CH, N.
[0095] In some embodiments, R4 is selected from the following group: hydrogen, halogen, cyano, hydroxyl, amino, C1-C5 alkyl, halogenated C1-C5 alkyl, C1-C5 alkoxy, halogenated C1-C5 alkoxy, C3-C8 cycloalkyl, -CH2R5, -(CH2)2R5, -(CH2)3R5 or 3-8 membered heterocyclyl.
[0096] In some embodiments, D, E, F, and G are CH.
[0097] In some embodiments, the R1 is -NHR7;
[0098] Wherein, R7 is -CH2R 10 ; R 10 The definition of is as mentioned above.
[0099] In another preferred embodiment, the R 10 Selected from the following groups: cyano, C1-C5 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, C3-C 10 Cycloalkyl, 4-7 membered heterocyclic group, C6-C 10Aryl; wherein the aryl is replaced by one or more CR 11 Replacement; R 11 The definition of is as mentioned above.
[0100] In some embodiments, the linker is selected from the group consisting of: wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m is independently 0, 1 or 2; and each U and W is independently selected from the group consisting of N or CH.
[0101] In another preferred embodiment, the Linker is selected from the following group:
[0102] wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m is independently 0, 1 or 2; and each U and W is independently selected from the group consisting of N or CH.
[0103] In some embodiments, the compound has a structure shown in formula (II) or formula (III):
[0104] Wherein, U and W are independently selected from: CH or N;
[0105] X, Y are independently selected from: CH, N or CR3;
[0106] Z is selected from: CH2 or CO;
[0107] n, m are independently selected from: 0 or 1.
[0108] In some embodiments, the compound is selected from the group consisting of:
[0109] In the third aspect of the present invention, a pharmaceutical composition is provided, characterized in that it comprises
[0110] (1) a compound as described in the first or second aspect of the present invention as an active ingredient, or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof; and
[0111] Optional (2) a pharmaceutically acceptable carrier.
[0112] In the fourth aspect of the present invention, a compound as described in the first or second aspect of the present invention, or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule thereof, or a use of the pharmaceutical composition as described in the third aspect of the present invention is provided, characterized in that it is used to prepare a CDK12 / 13 protein kinase degrader.
[0113] In the fifth aspect of the present invention, a compound as described in the first or second aspect of the present invention, or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule thereof, or a pharmaceutical composition as described in the third aspect of the present invention is provided, characterized in that it is used to prepare a drug for preventing and / or treating diseases mediated by CDK12 / 13 serine / threonine protein kinase.
[0114] In some embodiments, the disease mediated by CDK12 / 13 serine / threonine protein kinase is selected from the group consisting of prostate cancer, breast cancer, uterine cancer, ovarian cancer, non-small cell lung cancer, small cell lung cancer, Ewing sarcoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, liver cancer, skin cancer, epithelial cell carcinoma, gastrointestinal stromal tumor, leukemia, histiocytic lymphoma, nasopharyngeal carcinoma, head and neck tumors, colon cancer, rectal cancer, and glioma.
[0115] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0116] Figure 1 shows (A) the WB results of CDK12 and CDK13 protein degradation in MDA-MB-231 cells treated with some compounds at a concentration of 0.1 μM for 15 hours; (B) the WB results of CDK12 and CDK13 protein degradation in MDA-MB-231 cells treated with some compounds at a concentration of 0.3 μM for 15 hours; (C) the CDK12 / 13 levels were quantified by the grayscale values of the bands in the WB result image (Figure A) using the control group DMSO as a reference standard; (D) the CDK12 / 13 levels were quantified by the grayscale values of the bands in the WB result image (Figure B) using the control group DMSO as a reference standard.
[0117] Figure 2 shows (A) the time-dependent degradation of CDK12 and CDK13 proteins in MDA-MB-231 cells by representative compounds; (B) WB determination results of intracellular CDK12 / 13 protein levels after treatment of MDA-MB-231 cells with different concentrations of representative compounds for 15 hours.
[0118] FIG3 shows the results of the determination of the inhibitory activity of the compounds on triple-negative breast cancer cells MDA-MB-231.
[0119] Figure 4 shows (A) Western blot analysis of CDK12 and CDK13 protein degradation in 22RV1 cells treated with some compounds at a concentration of 500 nM for 6 hours. (B) Compound YJZ9069 dose-dependently degrades CDK12 and CDK13 proteins in 22RV1 cells and dose-dependently inhibits phosphorylation of RNA polymerase II (RNA Pol II) at the C-terminal serine 2 (phoSer2). (C) Western blot analysis of CDK12 and CDK13 protein degradation in LnCap cells treated with some compounds at a concentration of 500 nM for 6 hours. (D) Protein levels were quantified by grayscale analysis of the bands in the Western blot images (Panels A and C), using the DMSO control as the reference standard.
[0120] Figure 5 shows the WB assay results of intracellular CDK12 and CDK13 protein levels in 22RV1 cells after treatment with representative compounds YJZ9069, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205, and YJZ1206 at different concentrations for 6 hours.
[0121] FIG6 shows the results of the assay of the proliferation inhibitory activity of the compounds on the prostate cancer cell line VCap. DETAILED DESCRIPTION
[0122] After extensive and in-depth research, the inventors unexpectedly discovered a class of trans-1,4-cyclohexanediamine compounds. A series of biological activity tests revealed their excellent CDK12 / 13 inhibitory properties, leading to the completion of the present invention.
[0123] The experimental methods in the following examples of the present invention, where specific conditions are not specified, are generally carried out under conventional conditions or conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.
[0124] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0125] The terms "comprise," "comprising," and "having," and any variations thereof, are intended to cover non-exclusive inclusions. For example, a process, method, apparatus, product, or device comprising a series of steps is not limited to the listed steps or modules but may optionally include steps not listed, or other steps inherent to the process, method, product, or device.
[0126] In this application, the term "plurality" refers to two or more. "And / or" describes the relationship between related objects, indicating that three possible relationships exist. For example, "A and / or B" can represent: A exists alone, A and B exist simultaneously, and B exists alone. The character "three" generally indicates that the related objects are in an "or" relationship.
[0127] In the compounds of the present invention, when any variable (such as R 10 、R 11 If a substituent (e.g., ) occurs more than once in any component, its definition at each occurrence is independent of its definition at every other occurrence. Likewise, combinations of substituents and variables are permissible so long as such combinations result in a stable compound. A line drawn from a substituent into the ring system indicates that the indicated bond may be attached to any substitutable ring atom. If the ring system is polycyclic, this means that such bonds may be attached only to any suitable carbon atom in an adjacent ring. It will be understood that one of ordinary skill in the art can select substituents and substitution patterns in the compounds of the present invention to provide compounds that are chemically stable and readily synthesized from readily available starting materials using techniques in the art and the methods set forth below. If a substituent is itself substituted with more than one group, it will be understood that these groups may be on the same carbon atom or on different carbon atoms so long as the structure is stable.
[0128] As used herein, the term "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, the definition of "C1-C8" in "C1-C8 alkyl" includes groups having 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms in a straight or branched arrangement. The term "cycloalkyl" refers to a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms. For example, "cycloalkyl" includes cyclopropyl, methyl-cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, cyclohexyl, and the like.
[0129] As used herein, the term "alkenyl" includes straight or branched alkenyl groups. For example, C2-C6 alkenyl refers to a straight or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.
[0130] As used herein, the term "alkynyl" includes straight or branched chain alkynyl groups. For example, C2-C6 alkynyl refers to a straight or branched chain alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, butynyl, or the like.
[0131] As used herein, the term "cycloalkyl" refers to a cyclic saturated aliphatic hydrocarbon group having a specific number of carbon atoms. 10Alkenyl refers to a cyclic saturated aliphatic hydrocarbon group having 3 to 10 carbon atoms. It can be a monocyclic ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or similar groups. It can also be a bicyclic ring, such as a bridged ring or a spiro ring.
[0132] As used herein, the term "heterocyclyl" or "heterocycloalkyl" refers to a saturated or partially saturated cyclic group having a specific number of ring atoms (e.g., 3-10 ring atoms), wherein 1-3 atoms are heteroatoms selected from N, S, and O. It can be a monocyclic, bicyclic, or polycyclic ring, such as a fused ring, a bridged ring, or a spirocyclic ring. Specific examples include oxetanyl, azetidinyl, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl, and pyrrolidinyl.
[0133] As used herein, the term "alkylamino" refers to an amino group substituted by an alkyl group. For example, a "C1-C6 alkylamino" refers to an amino group substituted by a C1-C6 alkyl group, which may be monosubstituted or disubstituted; for example, methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di-tert-butylamino, etc.
[0134] As used herein, the term "alkoxy" refers to a group having an alkyl-oxy structure. For example, "C1-C6 alkoxy" refers to a linear or branched alkoxy group having 1 to 6 carbon atoms, including methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, and the like.
[0135] As used herein, the term "haloalkyl" represents an alkyl group wherein one or more hydrogen atoms are replaced by a halogen, wherein alkyl is as defined above.
[0136] As used herein, the term "haloalkoxy" represents an alkoxy group having one or more hydrogen atoms replaced by a halogen, wherein alkoxy is as defined above.
[0137] As will be understood by those skilled in the art, "halogen" as used herein is intended to include F, Cl, Br and I. More preferably, the halogen or halogen atom is selected from F, Cl and Br. "Halogenated" means substituted with an atom selected from F, Cl, Br, and I.
[0138] Unless otherwise specified as "substituted or unsubstituted", the groups of the present invention may be substituted by substituents selected from the following groups: halogen, nitrile, nitro, hydroxyl, amino, C1-C6 alkyl-amino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C2-C6 alkenyl, halogenated C2-C6 alkynyl, halogenated C1-C6 alkoxy, allyl, benzyl, C6-C12 Aryl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkoxy-carbonyl, phenoxycarbonyl, C2-C6 alkynyl-carbonyl, C2-C6 alkenyl-carbonyl, C3-C6 cycloalkyl-carbonyl, C1-C6 alkyl-sulfonyl, etc.
[0139] The present invention includes the free form of the compound of formula (I) (herein, formula (I) includes formula (II)), and also includes its pharmaceutically acceptable salts, its stereoisomers and its prodrug molecules. The term "free form" refers to the compound in a non-salt form. The pharmaceutically acceptable salts included include not only the exemplary salts of the specific compounds described herein, but also all typical pharmaceutically acceptable salts of the free form of the compound of formula (I) or formula (II). The free form of the specific salt of the compound can be isolated using techniques known in the art. For example, the free form can be regenerated by treating the salt with an appropriate dilute aqueous base solution, such as a dilute aqueous solution of NaOH, a dilute aqueous solution of potassium carbonate, a dilute aqueous ammonia and a dilute aqueous solution of sodium bicarbonate. The free form is somewhat different from its respective salt form in certain physical properties, such as solubility in polar solvents, but for the purposes of the invention, such acid salts and base salts are equivalent to their respective free forms in other pharmaceutical aspects.
[0140] Pharmaceutically acceptable salts of the present invention can be synthesized from compounds of the present invention containing a basic or acidic moiety by conventional chemical methods. Typically, salts of basic compounds are prepared by ion exchange chromatography or by reacting a free base with a stoichiometric amount or an excess of an inorganic or organic acid in the desired salt form in a suitable solvent or combination of solvents. Similarly, salts of acidic compounds are formed by reaction with a suitable inorganic or organic base.
[0141] Therefore, the pharmaceutically acceptable salts of the compounds of this invention include conventional non-toxic salts of the compounds of this invention formed by reacting an alkaline compound of this invention with an inorganic or organic acid. For example, conventional non-toxic salts include salts prepared from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, 2-acetoxy-benzoic acid, fumaric acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, trifluoroacetic ....
[0142] If the compound of the present invention is acidic, suitable "pharmaceutically acceptable salts" refer to salts prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum salts, ammonium salts, calcium salts, copper salts, ferric salts, ferrous salts, lithium salts, magnesium salts, manganic salts, manganous salts, potassium salts, sodium salts, zinc salts, and the like. Ammonium salts, calcium salts, magnesium salts, potassium salts, and sodium salts are particularly preferred. Salts derived from pharmaceutically acceptable organic non-toxic bases, including salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxocobalamin, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
[0143] Berg et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977: 66: 1-19, describe in more detail the preparation of the pharmaceutically acceptable salts described above and other typical pharmaceutically acceptable salts.
[0144] Unless otherwise specified, the structural formulas described herein are intended to include all isomeric forms (e.g., enantiomers, diastereomers, and geometric isomers (or conformers)): for example, R and S configurations containing asymmetric centers, (Z) and (E) isomers of double bonds, etc. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers (or conformers) are all within the scope of the present invention.
[0145] As used herein, the term "tautomer" refers to structural isomers of different energies that can interconvert across a low energy barrier. For example, proton tautomers (i.e., prototropy) include interconversion via proton migration, such as 1H-indazole and 2H-indazole. Valence tautomers include interconversion via reorganization of some of the bonding electrons.
[0146] As used herein, the term "solvate" refers to a complex in which the compound of the present invention is coordinated with solvent molecules to form a specific ratio.
[0147] As used herein, the term "hydrate" refers to a complex formed by coordination of a compound of the present invention with water.
[0148] The compound of the present invention can also be in the form of a prodrug. As used herein, the term "prodrug" refers to a compound that produces an active compound when metabolized (e.g., in vivo or in vitro). In some embodiments, the prodrug can be inactive, or have an activity lower than that of the free drug, but can provide favorable processing, administration or metabolic characteristics. The exemplary prodrug moiety of the present invention can be connected to the free drug by the hydroxyl, amino, phosphate or thiophosphate backbone of nucleotides, and can include ester, carbamate, carbonyl, thioester, amide, isocyanate, urea, thiourea or other physiologically acceptable metabolically unstable parts. In some embodiments, the prodrug is activated by enzymatic hydrolysis.
[0149] The present disclosure also includes isotopically labeled compounds that are identical to compounds of formula (I) (including compounds of formula (II)), but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of suitable isotopes for inclusion in the compounds of the present invention are hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as, but not limited to, 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 31 P. 35 S. 18 F and 36 Cl. With heavier isotopes (such as deuterium, i.e. 2 H) substitution may offer certain therapeutic advantages due to greater metabolic stability, such as greater in vivo half-life or lower dosage requirements, and may therefore be preferred in certain circumstances. The compounds may be combined with positron emitting isotopes for use in medical imaging and positron emission tomography (PET) studies to determine receptor distribution. Suitable positron emitting isotopes that may be incorporated into compounds of formula (I) or (II) are 11 C. 13 N. 15 O and 18 F. Isotopically labeled compounds of formula (I) or (II) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically labeled reagent in place of a non-isotopically labeled reagent.
[0150] The compounds disclosed herein can exist in solvated and unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the present invention is intended to encompass both solvated and unsolvated forms. In one embodiment, the compound is amorphous. In one embodiment, the compound is a single polymorph. In another embodiment, the compound is a mixture of polymorphs. In another embodiment, the compound is in crystalline form.
[0151] Pharmaceutical composition and administration method
[0152] Since the compounds of the present invention are CDK12 / 13 protein degraders, the compounds and pharmaceutically acceptable salts thereof, as well as other compound forms disclosed herein, can be included in pharmaceutical compositions useful for treating, preventing, and alleviating diseases associated with CDK12 / 13 activity.
[0153] The pharmaceutical composition of the present invention comprises an effective amount, such as a safe and effective amount of a compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. "Effective amount" refers to an amount sufficient to induce a desired biological response (e.g., to treat a condition). "Safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition comprises 1 to 3000 mg (active dose range of 3 to 30 mg / kg) of the compound of the present invention / dose, and more preferably comprises 10 to 2000 mg of the compound of the present invention / dose. Preferably, "one dose" is a capsule or tablet.
[0154] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances suitable for human use, which must have sufficient purity and sufficiently low toxicity. "Compatibility" in this article means that the components of the composition can be mixed with the compounds of the present invention and each other without significantly reducing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier parts include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose and cellulose acetate), gelatin, talc, solid lubricants (such as stearic acid and magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil), polyols (propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (Tween etc.), wetting agents (sodium lauryl sulfate etc.), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives and pyrogen-free water.
[0155] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administration routes include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) and topical administration.
[0156] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or bulking agents, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerol; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, some complex silicates, and sodium carbonate; (e) retarding solvents, such as paraffin; (f) absorption promoters, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets, and pills, the dosage form may also include a buffer.
[0157] Solid dosage forms, such as tablets, dragees, capsules, pills, and granules, can be prepared from coating and shell materials, such as enteric coatings and other materials well known in the art. They may contain opacifiers, and the active compound or compounds in such compositions that are released in a delayed manner in a portion of the digestive tract. Examples of useful embedding components are polymeric substances and waxes. If desired, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0158] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs. In addition to the active compound, the liquid dosage form may contain an inert diluent commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof.
[0159] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0160] Suspensions, in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures thereof.
[0161] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0162] Topical dosage forms for the compounds of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers or propellants (if required).
[0163] The compounds of the present disclosure may be administered alone or in combination with other pharmaceutically acceptable compounds.
[0164] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is suitable for use in a mammal (e.g., a human) in need of treatment, wherein the dosage is a dosage that is considered pharmaceutically effective at the time of administration. For a 60 kg human, the daily dosage is generally 1-2000 mg, preferably 6-600 mg. Of course, the specific dosage should also be determined by taking into account factors such as the route of administration and the patient's health status, all of which are within the skill of a skilled physician.
[0165] Uses and treatments
[0166] As described above, the compounds of the present invention are CDK12 / 13 protein degraders, and thus the compounds or compositions comprising the compounds can be used to treat, prevent, and alleviate diseases associated with CDK12 / 13 activity or abnormal expression. In some embodiments, disclosed herein are uses of the compounds of the present invention in the preparation of medicaments for preventing and / or treating diseases mediated by CDK12 / 13 serine / threonine protein kinases. In some embodiments, disclosed herein are compounds of the present invention for preventing and / or treating diseases mediated by CDK12 / 13 serine / threonine protein kinases. In some embodiments, disclosed herein are methods for treating diseases mediated by CDK12 / 13 serine / threonine protein kinases in subjects in need thereof, comprising administering to the subject an effective amount of a compound of the present invention. In some embodiments, the disease mediated by CDK12 / 13 serine / threonine protein kinase comprises prostate cancer, breast cancer, uterine cancer, ovarian cancer, non-small cell lung cancer, small cell lung cancer, Ewing sarcoma, lung adenocarcinoma, squamous cell lung cancer, pancreatic cancer, liver cancer, skin cancer, epithelial cell carcinoma, gastrointestinal stromal tumor, leukemia, histiocytic lymphoma, nasopharyngeal carcinoma, head and neck cancer, colon cancer, rectal cancer, glioma.
[0167] When used for the purposes and methods disclosed herein, the disclosed compounds and compositions can be used in combination with other known therapies. As used herein, "combination" administration refers to delivering two (or more) different treatments to a subject while the subject is suffering from a condition, for example, after the subject is diagnosed with the condition and before the condition is cured or eliminated, or the treatment is stopped for other reasons. In some embodiments, when the delivery of the second treatment begins, the delivery of one treatment is still ongoing, so there is overlap in administration. This is sometimes referred to as "simultaneous" or "parallel delivery" in this article. In other embodiments, the delivery of one treatment ends before the delivery of another treatment begins. In some embodiments of any one case, due to the combined administration, the treatment is more effective. For example, the second treatment is more effective, for example, the same effect can be seen with less second treatment compared to when the second treatment is performed in the absence of the first treatment, or the second treatment can alleviate symptoms to a greater extent, or similar situations are observed for the first treatment. In some embodiments, the delivery causes a reduction in symptoms or other parameters related to the condition that is greater than the reduction observed for a treatment delivered in the absence of another treatment. The effects of the two treatments can be partially added, fully added, or greater than added. Delivery can be such that the effects of the first treatment delivered are still detectable when the second treatment is delivered.
[0168] The compounds disclosed herein or compositions and at least one additional therapeutic agent can be administered simultaneously, in the same or separate compositions, or in sequence. For sequential administration, the compounds described herein can be administered first, and the additional agent can be administered subsequently, or the order of administration can be reversed.
[0169] In some embodiments, the compounds described herein are administered in combination with other treatment modalities, including surgery, radiation, transplantation (e.g., stem cell transplantation, bone marrow transplantation), chemotherapy, immunotherapy, cryotherapy, and / or thermotherapy. Such combination therapies can allow for lower doses of the administered agent and / or other agents, thereby avoiding possible toxicities or complications associated with various therapies.
[0170] In some embodiments, the compounds described herein are administered with at least one additional therapeutic agent, such as a chemotherapeutic agent. In certain embodiments, the compounds described herein are administered in combination with one or more additional chemotherapeutic agents. The chemotherapeutic agent can be a chemotherapeutic agent identified in the "A to Z List of Cancer Drugs" published by the National Cancer Institute.
[0171] The main advantages of the present invention are:
[0172] 1. The cell cycle-dependent protein kinase 12 / 13 (CDK12 / 13) degrader provided by the present invention can effectively degrade CDK12 and CDK13 protein kinases, and can be used to prepare drugs for preventing or treating diseases mediated by CDK12 and / or CDK13 protein kinases, such as prostate cancer, breast cancer, uterine cancer, ovarian cancer, non-small cell lung cancer, small cell lung cancer, Ewing sarcoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, liver cancer, skin cancer, epithelial cell carcinoma, gastrointestinal stromal tumor, leukemia, histiocytic lymphoma, nasopharyngeal carcinoma, head and neck tumors, colon cancer, rectal cancer, glioma, etc.
[0173] 2. The cell cycle-dependent protein kinase 12 / 13 (CDK12 / 13) degrading agent provided by the present invention has strong degradation activity.
[0174] 3. The cell cycle-dependent protein kinase 12 / 13 (CDK12 / 13) degrader provided by the present invention has high protein kinase degradation selectivity.
[0175] The present invention is further described in detail below with reference to specific embodiments.
[0176] Example 1: Compound zlc-4-77
[0177] Step 1: Preparation of intermediate 3-86
[0178] In a three-necked round-bottom flask, to a system of tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate (1.02 g, 3 mmol) in anhydrous DMSO (15 mL) were added trans-cyclohexane-1,4-diamine 2 (1.2 g, 10.5 mmol), potassium phosphate (1.3 g, 6 mmol), CuI (57 mg, 0.3 mmol), and D-proline (35 mg, 0.3 mmol) in sequence. After completion, the mixture was replaced with argon three times and the temperature was raised to 100°C. After completion of the reaction monitored by TLC, the mixture was brought to room temperature, filtered through celite, and washed three times with DCM / MeOH (10:1). The filtrate was concentrated under reduced pressure, wet-loaded, and purified by silica gel normal phase chromatography to obtain the target compound 3-86 (off-white solid, 480 mg, 43% yield). 1H NMR (400MHz, DMSO-d6) δ6.74(d,J=8.8Hz,2H),6.49(d,J=8.9Hz,2H),4.88(d,J=8.2Hz,1H),3.42(t,J=5.1Hz,4H),3.03(s,1H),2.83(t,J=5.1H z,4H),2.76(s,1H),1.95(d,J=12.8Hz,2H),1.85(d,J=12.4Hz,2H),1.41(s,9H),1.26(q,J=10.9Hz,2H),1.11(q,J=11.6Hz,2H).HRMS(ESI)for C 21 H 34 N4O2[M+H] + ,calcd:375.2755,found:375.2739.
[0179] Step 2: Preparation of Intermediate 4-39
[0180] To a 100 mL round-bottom flask, 3-86 (1.38 g, 3.7 mmol) in DMF (7.5 mL) was added 5-cyano-2-fluoropyridine 3 (451 mg, 3.7 mmol) and Cs2CO3 (1.45 g, 4.44 mol). The mixture was allowed to react overnight at room temperature. After completion, the reaction was monitored by TLC, filtered, and the filtrate was concentrated under reduced pressure. Purification by normal phase chromatography on a silica gel column afforded intermediate 4-39 (white solid, 1.4 g, 80%). 1 H NMR (400MHz, DMSO-d6) δ8.37(s,1H),7.63(d,J=8.5Hz,1H),7.51(d,J=1Hz,1H),6.75(d,J=6.9Hz,2H),6.52(d,J=8.3Hz,3H),4. 92(s,1H),3.75(s,1H),3.42(s,4H),3.12(s,1H),2.83(s,4H),1.98(s,4H),1.41(s,9H),1.36–1.28(m,2H),1.25–1.17(m,2H).
[0181] Step 3: Preparation of Intermediate 4-44
[0182] In a 25 mL round-bottom flask, to a DMF (3 mL) system of 4-39 (1.438 g, 3 mmol) was added benzyl isocyanate 4 (1.2 g, 9 mmol) and DIPEA (1.6 mL) in sequence. After completion, the temperature was raised to 95°C. After 6 h, the reaction was monitored by TLC for completion. The mixture was brought to room temperature, concentrated under reduced pressure, and purified by normal phase chromatography on silica gel to obtain the target intermediate 4-44 (white solid, 1.3 g, 72% yield). 1 H NMR (400MHz, DMSO-d6) δ8.29(s,1H),7.60(d,J=9.0Hz,1H),7.46(d,J=6.6Hz,1H),7.28– 7.24(m,2H),7.18–7.14(m,3H),7.03–6.98(m,4H),6.46(d,J=8.7Hz,1H),5.58-5.56(m,1 H),4.26(t,J=11.9Hz,1H),4.14(d,J=5.4Hz,2H),3.45(s,5H),3.16(s,4H),1.90(d,J=11 .1Hz,2H),1.76(d,J=11.6Hz,2H),1.42(d,J=1.6Hz,9H),1.27(m,2H),1.14–1.04(m,2H).
[0183] Step 4: Preparation of Intermediate 4-46
[0184] In a 25 mL round-bottom flask, CF3COOH (1 mL) was added dropwise to a solution of 4-44 (1.83 g, 3 mmol) in CH2Cl2 (2 mL). The mixture was stirred at room temperature overnight. After completion of the reaction, the mixture was concentrated under reduced pressure, extracted with saturated sodium bicarbonate-CH2Cl2 / MeOH (10:1), dried over anhydrous sodium sulfate, and purified by silica gel column chromatography to obtain the target intermediate 4-46 (white solid, 1.43 g, 94%). 1H NMR(500MHz,DMSO-d6)δ8.29(s,1H),7.60(d,J=9.2Hz,1H),7.48(s,1H),7.28–7.25(m,2H ),7.18–7.15(m,3H),7.00–6.95(m,4H),6.47(d,J=8.9Hz,1H),5.56(s,1H),4.26(m,1H), 4.14(d,J=5.9Hz,2H),3.48(s,1H),3.37–3.34(m,1H),3.11–3.09(m,4H),2.85–2.83(m,4 H),1.90(d,J=11.4Hz,2H),1.76(d,J=10.7Hz,2H),1.33–1.27(m,2H),1.13–1.06(m,2H).
[0185] Step 5: Preparation of Intermediate 4-65
[0186] In a 25 mL round-bottom flask, potassium carbonate (83 mg, 0.6 mmol) and 1-Boc-4-bromomethylpiperidine (167 mg, 0.6 mmol) were added to a DMF (2 mL) system of 4-46 (153 mg, 0.3 mmol) in sequence. After completion, the temperature was raised to 80°C and stirred overnight. After completion of the reaction, the reaction solution was concentrated under reduced pressure and purified by normal phase chromatography on a silica gel column to obtain the target intermediate 4-65 (white solid, 110 mg, 52%). 1 H NMR (500MHz, DMSO-d6) δ8.29(d,J=2.1Hz,1H),7.60(d,J=8.7Hz,1H),7.49(d,J=6.6Hz,1H),7.28–7.26(m,2H),7.1 8–7.14(m,3H),7.03–6.96(m,4H),6.46(d,J=8.8Hz,1H),5.59(t,J=5.6Hz,1H),4.28–4.23(s,1H),4.14–4.13(d,J= 6.0Hz,2H),3.92(s,2H),3.50(s,1H),3.17(s,4H),2.47(s,4H),2.17(d,J=6.6Hz,2H),1.90(d,J=9.7Hz,2H),1.77 –1.68(m,5H),1.39(s,9H),1.33–1.26(m,2H),1.13–1.08(m,2H),0.98–0.94(m,2H),0.84–0.81(m,2H).MS(ESI)for C 41 H 55 N8O3[M+H] +,calcd:707.4,found:707.5.
[0187] Step 6: Preparation of compound zlc-4-77
[0188] In a 25 mL round-bottom flask, CF3COOH (0.3 mL) was added dropwise to a CH2Cl2 (1 mL) system of 4-65 (79 mg, 0.112 mmol) and stirred at room temperature overnight. After the reaction was completed, the solvent was concentrated under reduced pressure, and DMF (2 mL), 2-(2,6-dioxo-piperidin-3-yl)-5-fluoro-isoindole-1,3-dione (31 mg, 0.112 mmol), and DIPEA (0.023 mL, 0.135 mmol) were added in sequence. The temperature was raised to 105 ° C. After monitoring the completion of the reaction, the temperature was moved to room temperature, concentrated under reduced pressure, and purified by normal phase chromatography on silica gel to obtain the target product zlc-4-77 (yellow solid, 30 mg, 32%). 1 H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.29(d,J=2.1Hz,1H),7.65(d,J=8.5H z,1H),7.60(d,J=8.4Hz,1H),7.47(s,1H),7.31(s,1H),7.28–7.25(m,2H),7 .23(d,J=8.6Hz,1H),7.18–7.15(m,3H),7.01–6.97(m,4H),6.51–6.44(m,1H ),5.57(t,J=5.2Hz,1H),5.06(dd,J=12.8,5.4Hz,1H),4.26(t,J=11.8Hz,1H) ,4.15(d,J=5.7Hz,2H),4.05(d,J=12.7Hz,2H),3.48(s,1H),3.19(s,4H),2. 97(t,J=12.0Hz,2H),2.93–2.84(m,1H),2.63–2.53(m,2H),2.52–2.50(m,4H ),2.20(d,J=6.1Hz,2H),2.04–1.99(m,1H),1.90(d,J=10.3Hz,3H),1.82(d, J=12.5Hz,2H),1.76(d,J=10.6Hz,2H),1.35–1.28(m,2H),1.17–1.05(m,4H). 13C NMR (151MHz, DMSO) δ172.81,170.12,167.64,166.97,159.25,156.80,155.01,15 3.10,150.15,141.33,134.05,131.50,128.15,128.02,126.69,126.23,125.01, 119.12,117.58,117.35,115.34,107.74,93.99,63.71,53.21,52.91,48.73,47. 70,47.27,43.47,32.49,31.31,30.98,30.20,29.64,22.20,14.09.HRMS(ESI)for C 49 H 55 N 10 O5[M+H] + ,calcd:863.4351,found:863.4360.
[0189] Example 2: Preparation of compound zlc-4-79
[0190] Step 1: Preparation of intermediate 4-66
[0191] In a 25 mL round-bottom flask, HATU (137 mg, 0.36 mmol), DIPEA (0.1 mL, 0.6 mmol) and 1-N-Boc-3-azetidinecarboxylic acid (67 mg, 0.33 mmol) were added sequentially to a solution of 4-46 (153 mg, 0.3 mmol) in DMF (2 mL). The reaction was stirred at room temperature and monitored for completion. Water was added to quench the precipitated solid, which was filtered and washed with the filter cake (CH2Cl2 / MeOH=10:1), dried over anhydrous sodium sulfate, and purified by normal chromatography on silica gel to give the target intermediate 4-66 (white solid, 120 mg, 59%). 1H NMR(500MHz,DMSO-d6)δ8.29(d,J=2.1Hz,1H),7.60(d,J=9.2Hz,1H),7.48(s,1H),7.28–7.25(m,2H),7.1 8–7.14(m,3H),7.03–6.99(m,4H),6.46(d,J=8.9Hz,2H),5.61–5.59(m,1H),4.28–4.23(m,1H),4.14(d,J= 5.8Hz,2H),3.72–3.68(m,1H),3.63–3.60(m,4H),3.40(s,2H),3.19–3.17(m,3H),3.16–3.12(m,4H),1.90 (d,J=10.9Hz,2H),1.76(d,J=12.3Hz,2H),1.37(s,9H),1.32–1.27(m,2H),1.13–1.06(m,2H).MS(ESI)for C 39 H 49 N8O4[M+H] + ,calcd:693.4,found:692.8.
[0192] Step 2: Preparation of compound zlc-4-79
[0193] The synthesis method is the same as that of step f in Example 1.
[0194] 1H NMR (600MHz, DMSO-d6) δ11.07(s,1H),8.29(d,J=2.2Hz,1H),7.66(d,J=8.3Hz,1H),7.60(d,J=8.2Hz,1H),7.51–7.44(m,1H),7.28–7. 26(m,2H),7.19–7.15(m,3H),7.05–7.01(m,4H),6.84(d,J=1.8Hz,1H),6.70(dd,J=8.4,2.0Hz,1H),6.47(d,J=8.9Hz,1H),5.58(t,J=5 .5Hz,1H),5.06(dd,J=12.8,5.4Hz,1H),4.28–4.25(m,3H),4.18–4.15(m,4H),4.00–3.97(m,1H),3.65(s,2H),3.49(s,3H),3.22(m,4 H),2.91–2.84(m,1H),2.59–2.53(m,2H),2.03–2.00(m,1H),1.91(d,J=10.3Hz,2H),1.77(d,J=10.6Hz,2H),1.31(m,2H),1.10(m,2H). 13 C NMR (151MHz, DMSO) δ172.80,170.10,169.35,167.43,167.15,159.24,156.77,154. 98,153.10,149.92,141.30,133.80,131.60,128.76,128.03,126.71,126.25,124. 83,119.12,117.24,115.97,114.30,104.56,94.00,53.63,52.92,48.72,48.07,47 .75,44.42,43.48,41.30,31.30,31.21,30.98,30.20,22.19,14.09.HRMS(ESI)for C 47 H 49 N 10 O6[M+H] + ,calcd:849.3831,found:849.3839.
[0195] Example 3: Preparation of compound zlc-4-91
[0196] Step 1: Preparation of Intermediate 4-64
[0197] p-Bromoiodobenzene (5.0 g, 17.7 mmol), N-BOC-trans-1,4-cyclohexanediamine (3.2 g, 14.7 mmol), Pd2(dba)3 (1.37 g, 1.5 mmol), Xantphos (1.7 g, 2.94 mmol), and tert-ButONa (2.8 g, 29.4 mmol) were dissolved in 150 mL of toluene. The atmosphere was replaced with argon three times, and the reaction mixture was heated to 100°C overnight. After completion of the reaction, the reaction mixture was filtered through Celite and concentrated under reduced pressure. Column chromatography afforded the target compound 4-64 (3.9 g, 72% yield, yellow solid). 1 H NMR (500MHz, DMSO-d6) δ7.16–7.13(m,2H),6.79(d,J=7.9Hz,1H),6.49(dd,J=8.9,2.0Hz,2H),5.63(d,J =8.0Hz,1H),3.21–3.19(m,1H),3.06–3.03(m,1H),1.93(d,J=12.6Hz,2H),1.77(d,J=12.5Hz,2H),1.28 –1.21(m,1H),1.16–1.11(m,2H).
[0198] Step 2: Preparation of Intermediate 4-68
[0199] Intermediate 4-64 (3.9 g, 10.6 mmol) was dissolved in 4 mL of DMF, and benzyl isocyanate (4.2 g, 31.7 mmol) and DIPEA (1.59 g, 12.3 mmol) were added. The mixture was reacted at 95°C for 5 h. The solvent was evaporated, and the target compound 4-68 was obtained by column chromatography (3.7 g, yellow solid, 69% yield). 1 H NMR (500MHz, DMSO-d6) δ7.64–7.62(m,2H),7.27–7.25(m,2H),7.19–7.15(m,3H),7.12–7.10(m,2H),6.69(d,J=7.9Hz,1H),6.01(t,J=6.1Hz,1H ),4.24–4.16(m,1H),4.13(d,J=6.1Hz,2H),2.94(m,1H),1.72(d,J=11. 7Hz, 4H), 1.34 (s, 9H), 1.24–1.21 (m, 2H), 1.03–0.96 (d, J = 12.1Hz, 2H).
[0200] Step 3: Preparation of Intermediate 4-69
[0201] Intermediate 4-68 (3.7 g, 7.3 mmol) was dissolved in 5 mL of DCM, and 2.5 mL of trifluoroacetic acid (TFA) was added. After heating to 55°C and reflux for 6 h, the solvent was evaporated under reduced pressure and the target compound 4-69 was obtained by column chromatography (yellow solid 2.5 g, 70% yield). 1 H NMR(500MHz,DMSO-d6)δ7.65–7.63(m,2H),7.28–7.25(m,2H),7.19–7.11(m,5H),6.04(m,1H),4.23–4.18(m,1H),4 .12(d,J=5.3Hz,2H),2.79(m,1H),1.89(d,J=12.8Hz,2H),1.79(d,J=12.2Hz,2H),1.38(m,2H),1.09–1.01(m,2H).
[0202] Step 4: Preparation of Intermediate 4-87
[0203] Compound 4-69 (2.5 g, 5.1 mmol) was dissolved in 15 mL of DMF, and 5-cyano-2-fluoropyridine (744 mg, 6.1 mol) and Cs2CO3 (2.0 g, 6.1 mol) were added. The mixture was stirred at room temperature for 15 minutes and then heated to 60°C for 40 minutes. After completion of the reaction, the solvent was evaporated under reduced pressure and purified by column chromatography to obtain the target compound 4-87 (white solid, 1.9 g, 70% yield). 1 H NMR(500MHz,DMSO-d6)δ8.30(d,J=2.2Hz,1H),7.65–7.60(m,3H),7.48(d,J =6.5Hz,1H),7.29–7.26(m,2H),7.19–7.13(m,5H),6.47(d,J=8.9Hz,1H),6 .03(t,J=5.9Hz,1H),4.30–4.23(m,1H),4.14(d,J=6.0Hz,2H),3.51(s,1H) ,1.91(d,J=11.0Hz,1H),1.78(d,J=11.4Hz,2H),1.31(m,2H),1.10(m,2H).
[0204] Step 5: Preparation of Intermediate 4-88
[0205] To a 25 mL Shrek flask, compound 4-87 (1.51 g, 3 mmol), tert-butyl 4-piperazin-1-ylpiperidine-1-carboxylate (986 mg, 3.6 mmol), Pd(dba) (274 mg, 0.3 mmol), Xantphos (347 mg, 0.6 mmol), and tert-ButONa (576 g, 6 mmol) were added sequentially. The atmosphere was replaced with argon three times, and toluene (6 mL) was added. The temperature was raised to 110°C and the reaction was allowed to proceed overnight. After completion, the mixture was filtered through Celite, concentrated under reduced pressure, and purified by column chromatography to obtain the target compound 4-88 (yellow solid, 1.27 g, 61%). 1 H NMR (500MHz, DMSO-d6) δ8.29(d,J=1.7Hz,1H),7.60(d,J=8.5Hz,1H),7.48(s,1H),7.28–7.25( m,2H),7.18–7.14(m,3H),7.00–6.95(m,5H),6.46(d,J=9.0Hz,1H),5.59(s,1H),4.28–4.23(m ,1H),4.14(d,J=5.9Hz,2H),3.95(s,2H),3.16(s,4H),2.73(s,1H),2.61(s,4H),2.40–2.37(m ,1H),1.90(d,J=10.8Hz,2H),1.77(m,4H),1.39(s,9H),1.33–1.23(m,6H),1.13–1.05(m,2H).
[0206] Step 6: Preparation of compound zlc-4-91
[0207] The synthesis method is the same as that of step f in Example 1.
[0208] 1H NMR (600MHz, DMSO-d6) δ11.11(s,1H),8.29(d,J=2.2Hz,1H),7.71(d,J=11.4Hz,1H),7.59(d,J=8.4Hz,1H),7.45(m,2H),7.28–7.25(m,2H),7 .18–7.15(m,3H),7.01–6.96(m,4H),6.46(d,J=8.9Hz,1H),5.57(m,1H),5.11(dd,J=12.9,5.4Hz,2H),4.28–4.26(m,1H),4.15(d,J=5.7Hz,2H ),3.67(d,J=11.5Hz,2H),3.49(s,1H),3.19(s,4H),2.93–2.86(m,3H),2.66(s,4H),2.61–2.58(m,1H),2.54–2.52(d,J=13.2Hz,1H),2.49–2 .44(d,J=15.7Hz,1H),2.04–2.02(m,1H),1.93–1.90(m,4H),1.76(d,J =10.4Hz,2H),1.62–1.57(m,2H),1.33–1.27(m,2H),1.13–1.07(d,2H). 13 C NMR (151MHz, DMSO) δ172.76,169.91,166.69,166.21,159.25,158.09,156.81,156. 41,153.09,150.15,145.47,141.34,131.50,128.77,128.14,128.01,126.69,126. 22,122.98,119.11,115.29,113.72,112.00,111.83,93.99,59.76,52.92,49.33,4 9.05,48.77,48.02,43.48,31.31,30.96,30.20,27.88,22.09,14.09.HRMS(ESI)for C 48 H 52 N 10 O5[M+H] + ,calcd:867.4101,found:867.4104.
[0209] Example 4: Preparation of compound zlc-4-93
[0210] The synthesis method is shown in Example 1.
[0211] 1H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.29(d,J=2.2Hz,1H),7.66(d,J=8.5Hz,1H),7.60(d,J=8.2Hz,1H),7.47(s,1H),7.33(s,1H),7.27– 7.25(m,3H),7.18–7.15(m,3H),7.00–6.95(m,4H),6.46(d,J=8.9Hz,1H),5.58–5.56(m,1H),5.08–5.05(dd,J=12.8,5.5Hz,1H),4.28–4.2 3(m,1H),4.14(d,J=5.8Hz,2H),4.09(d,J=12.5Hz,2H),3.48(s,1H),3.17(s,4H),3.01–2.97(m,2H),2.91–2.85(m,1H),2.63(s,4H),2.60 –2.50(m,4H),2.03–2.00(m,1H),1.90(d,J=10.3Hz,4H),1.76(d,J=10.5Hz,2H),1.51–1.46(m,2H),1.33–1.27(m,2H),1.12–1.06(m,2H). 13 C NMR (151MHz, DMSO) δ172.81,170.11,167.61,166.96,159.24,156.80,154. 75,153.09,150.14,141.34,134.04,131.49,128.14,128.01,126.69,126.2 2,125.01,119.12,117.70,115.30,107.82,93.98,59.76,52.90,48.74,48 .00,46.61,43.47,31.30,30.98,30.19,27.21,22.19,14.09.HRMS(ESI)for C 48 H 53 N 10 O5[M+H] + ,calcd:849.4195,found:849.4199.
[0212] Example 5: Preparation of compound zlc-5-6
[0213] The synthesis method is shown in Example 1.
[0214] 1H NMR (500MHz, DMSO-d6) δ11.07(s,1H),8.29(d,J=2.2Hz,1H),7.64(d,J=8.3Hz,1H),7.60(d,J=10.2Hz,1H),7.47(d,J=7.0Hz,1H),7.28–7.25(m ,2H),7.18–7.15(m,3H),7.02–6.97(m,4H),6.78(d,J=1.5Hz,1H),6.65 (dd,J=8.4,1.7Hz,1H),6.47(d,J=8.8Hz,1H),5.58(m,1H),5.07–5.03( m,1H),4.29–4.24(m,1H),4.17–4.14(m,4H),3.73–3.70(m,2H),3.50(s ,1H),3.50-3.46(m,1H),3.19(s,4H),3.05(s,1H),2.90–2.84(m,1H),2 .66(d,J=5.4Hz,2H),2.60–2.54(m,6H),2.02–2.00(m,1H),1.91(d,J=9 .7Hz,2H),1.77(d,J=10.2Hz,2H),1.33–1.26(m,2H),1.13–1.06(m,2H). 13 C NMR (151MHz, DMSO) δ172.80,170.11,167.49,167.18,159.24,156.80,155. 19,153.10,150.12,141.34,133.82,131.50,128.22,128.02,126.69,126.2 3,124.80,119.12,116.68,115.42,114.06,104.35,93.98,61.76,55.75,52 .85,48.70,47.63,43.46,31.30,30.98,30.20,27.00,22.21.HRMS(ESI)for C 47 H 51 N 10 O5[M+H] + ,calcd:835.4038,found:835.4043.
[0215] Example 6: Preparation of compound zlc-5-11
[0216] The synthesis method is shown in Example 1.
[0217] 1H NMR(500MHz,DMSO-d6)δ11.09(s,1H),8.31–8.28(m,1H),7.68(d,J=8.7Hz,1H),7.60(d,J=8.8Hz,1H),7.49(s,1H),7.34(s,1H),7.2 8–7.25(m,3H),7.18–7.15(m,3H),6.99(m,4H),6.46(d,J=8.8Hz,1H),5.59–5.57(m,1H),5.07(dd,J=12.8,5.4Hz,1H),4.28–4.14(m, 1H),4.14(d,J=5.6Hz,2H),3.79(d,J=9.4Hz,2H),3.44(m,4H),2.92–2.85(m,1H),2.75–2.70(m,2H),2.65(m,4H),2.60–2.56(m,2H) ,2.41–2.36(m,1H),2.03–2.00(m,1H),1.91(s,4H),1.76(d,J=11.0Hz,2H),1.53–1.51(m,2H),1.33–1.25(m,2H),1.13–1.06(m,2H). 13 C NMR (126MHz, DMSO) δ172.87,170.14,167.60,167.02,159.26,156.85,153.14,150.15,141.36,133.87,131.53,128.06,127.91,126.7 1,126.27,124.94,119.17,115.82,94.00,59.81,52.91,48.79,48.42,47.47,43.49,31.34,31.01,30.24,22.21,14.13.HRMS(ESI)for C 48 H 53 N 10 O5[M+H] + ,calcd:849.4195,found:849.4192.
[0218] Example 7: Preparation of compound zlc-5-15
[0219] The synthesis method is shown in Example 1.
[0220] 1H NMR (500MHz, DMSO-d6) δ11.09(s,1H),8.29(d,J=2.3Hz,1H),7.66(d,J=8.2Hz,1H),7.60(d,J=8.9Hz,1H),7.49(s,1H),7.2 8–7.25(m,2H),7.18–7.15(m,3H),7.03–6.98(m,4H),6.82(s,1H),6.67(d,J=8.4Hz,1H),6.46(d,J=8.9Hz,1H),5.62–5.60 (m,1H),5.08–5.04(m,1H),4.28–4.23(m,1H),4.14(d,J=5.2Hz,4H),3.92(s,2H),3.39(s,1H),3.23(s,4H),2.91–2.84(m, 1H),2.64–2.51(m,6H),2.02–2.01(m,1H),1.90(d,J=11.6Hz,2H),1.77–1.75(m,2H),1.35–1.22(m,3H),1.17–1.05(m,2H). 13 C NMR (126MHz, DMSO) δ172.87,170.17,167.51,167.20,159.26,156.83,154. 94,153.14,150.06,141.37,133.86,131.57,128.05,126.72,126.27,124.9 1,119.17,116.92,115.45,114.27,104.56,94.00,55.06,54.19,52.91,49 .16,48.74,47.40,43.49,31.33,31.01,30.23,22.23,14.13.HRMS(ESI)for C 46 H 49 N 10 O5[M+H] + ,calcd:821.3882,found:821.3884.
[0221] Example 8: Preparation of compound zlc-5-20
[0222] The synthesis method is shown in Example 1.
[0223] 1H NMR (500MHz, DMSO-d6) δ11.08(s,1H),8.29(d,J=1.8Hz,1H),7.65(d,J=8.4Hz,1H),7.60(d,J=8.6Hz,1H),7.48(d,J=5.9Hz,1H),7.28–7.25(m,2H),7 .19–7.15(m,3H),7.01–6.98(m,5H),6.86(d,J=8.6Hz,1H),6.47(d,J=8.9 Hz,1H),5.59(t,J=5.7Hz,1H),5.06(dd,J=12.8,5.3Hz,1H),4.29–4.23(m, 1H),4.15(d,J=5.7Hz,2H),3.75–3.72(m,1H),3.61–3.58(m,1H),3.50–3. 38(m,2H),3.29–3.22(m,5H),3.05–2.98(m,1H),2.91–2.85(m,1H),2.69–2 .61(m,4H),2.61–2.52(m,2H),2.31–2.27(m,1H),2.02–2.00(m,1H),1.91– 1.89(m,3H),1.77(d,J=10.5Hz,2H),1.33–1.27(m,2H),1.13–1.06(m,2H). 13 C NMR (126MHz, DMSO) δ172.89,170.22,167.75,167.29,159.27,156.85,153.15 ,151.81,150.13,141.38,134.04,131.56,128.29,126.72,126.27,124.96,1 19.18,115.80,115.48,115.25,105.63,94.01,63.55,52.92,52.03,51.35,4 8.71,47.64,47.05,43.50,31.34,31.03,30.24,28.89,22.29.HRMS(ESI)for C 47 H 51 N 10 O5[M+H] + ,calcd:835.4038,found:835.4036.
[0224] Example 9: Preparation of compound zlc-5-31
[0225] The synthesis method is shown in Example 1.
[0226] 1 H NMR (500MHz, DMSO-d6) δ11.10(s,1H),8.30(d,J=1.8Hz,1H),7.67(d,J=8.5Hz,1H),7.60(d,J=8.5Hz,1H),7.54–7.46(m,1H),7.34(s,1H),7.28 –7.24(m,3H),7.19–7.15(m,3H),7.05–7.00(m,4H),6.47(d,J=8.9Hz,1 H),5.60–5.59(m,1H),5.07(dd,J=12.8,5.3Hz,1H),4.29–4.24(m,1H),4 .15(d,J=5.5Hz,2H),4.08(d,J=12.6Hz,2H),3.71(s,2H),3.61(s,2H), 3.49(s,1H),3.23(s,2H),3.17(s,2H),3.11–3.02(m,3H),2.92–2.85(m ,1H),2.60–2.54(m,2H),2.03–2.00(m,1H),1.90(d,J=10.5Hz,2H),1.7 8–1.73(m,4H),1.67–1.60(m,2H),1.33–1.27(m,2H),1.13–1.06(m,2H). 13 C NMR(151MHz,DMSO)δ172.81,172.34,170.10,167.60,166.96,159.24,156.77,154 .82,153.09,149.92,141.30,134.05,131.60,128.70,128.02,126.70,126.24,125 .03,119.11,117.64,115.88,107.85,93.99,52.92,48.73,48.41,47.84,46.72,44 .62,43.48,41.07,36.80,31.30,30.98,30.20,27.42,22.19,14.09.HRMS(ESI)for C 49 H 53 N 10 O6[M+H] + ,calcd:877.4144,found:877.4139.
[0227] Example 10: Preparation of compound zlc-5-103
[0228] The synthesis method is shown in Example 1.
[0229] 1 H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.30–8.28(m,1H),7.68(d,J=8.5Hz,1H),7.60(d,J=8.6Hz,1H),7.47(s,1H),7.36(s,1H),7.28–7. 25(m,3H),7.18–7.15(m,3H),6.97(d,J=8.6Hz,2H),6.49(d,J=8.7Hz,2H),6.46(d,J=9.0Hz,1H),5.51(t,J=5.7Hz,1H),5.07(dd,J=12.8, 5.4Hz,1H),4.28–4.24(m,1H),4.15(d,J=5.9Hz,2H),3.98(t,J=7.1Hz,2H),3.70–3.68(m,2H),3.50–3.42(m,5H),3.38–3.37(m,2H),2.91 –2.85(m,1H),2.60–2.52(m,3H),2.02–2.00(m,1H),1.90(d,J=10.2Hz,2H),1.76(d,J=10.6Hz,2H),1.33–1.23(m,4H),1.12–1.06(m,2H). 13 C NMR (151MHz, DMSO) δ173.28,170.55,168.03,167.45,159.72,157.38,155. 70,153.58,151.37,141.79,134.31,131.92,128.50,127.19,127.15,126.7 1,125.37,119.59,118.93,118.37,112.19,108.49,94.46,56.10,54.60,53 .37,49.25,49.10,47.17,43.94,31.78,31.45,30.67,22.65.HRMS(ESI)for C 46 H 49 N 10 O5[M+H] + ,calcd:821.3882,found:821.3884.
[0230] Example 11: Preparation of compound zlc-5-104
[0231] The synthesis method is shown in Example 1.
[0232] 1H NMR (600MHz, DMSO-d6) δ11.07(s,1H),8.29(d,J=2.3Hz,1H),7.63(d,J=8.5Hz,1H),7.60(d,J=8.3Hz,1H),7.48(s,1H),7.28–7.25(m,3H),7 .21–7.15(m,4H),6.97(d,J=8.5Hz,2H),6.67(d,J=8.4Hz,2H),6.47(d,J=8.9Hz,1H),5.53(s,1H),5.05(dd,J=12.8,5.5Hz,1H),4.29–4.25 (m,1H),4.15(d,J=5.8Hz,2H),4.02(d,J=12.3Hz,2H),3.41(m,3H),3.10(m,2H),2.96–2.84(m,5H),2.59–2.53(m,4H),2.43(s,1H),2.28–2 .23(m,2H),2.01–1.97(m,2H),1.91–1.90(m,2H),1.79–1.75(m,5H),1.31–1.27(m,2H),1.24–1.23(m,2H),1.13–1.09(m,2H).HRMS(ESI)for C 51 H 57 N 10 O5[M+H] + ,calcd:889.4508,found:889.4515.
[0233] Example 12: Preparation of compound zlc-5-105
[0234] The synthesis method is shown in Example 1.
[0235] 1H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.29(d,J=2.3Hz,1H),7.64(d,J=8.6Hz,1H),7.60(d,J=8.0Hz,1H),7.48(s,1H),7.29–7.25(m,3H),7. 21(dd,J=8.7,2.1Hz,1H),7.18–7.14(m,3H),6.95(d,J=8.6Hz,2H),6.47–6.44(m,3H),5.47(t,J=5.5Hz,1H),5.06(dd,J=12.8,5.5Hz,1H),4. 27–4.23(m,1H),4.14(d,J=5.9Hz,2H),4.01(d,J=12.9Hz,2H),3.90(s ,4H),3.30(s,4H),2.95–2.91(m,2H),2.91–2.85(m,1H),2.60–2.52(m, 2H),2.27(s,1H),2.02–2.00(m,1H),1.90(d,J=12.1Hz,2H),1.75(d,J =11.8Hz,4H),1.30–1.24(m,4H),1.17–1.11(m,2H),1.08–1.06(m,2H). 13 C NMR(151MHz,DMSO)δ173.29,170.59,168.11,167.43,159.71,157.35,15 5.40,153.57,151.12,141.74,134.52,131.89,128.51,125.49,119.59,1 18.02,117.81,112.31,108.16,94.46,70.25,64.88,62.14,53.35,49.2 0,47.71,43.94,34.71,31.77,31.45,30.65,29.90,22.66.HRMS(ESI)for C 50 H 55 N 10 O5[M+H] + ,calcd:875.4351,found:875.4354.
[0236] Example 13: Preparation of compound zlc-5-106
[0237] The synthesis method is shown in Example 1.
[0238] 1H NMR (600MHz, DMSO-d6) δ11.07(s,1H),8.29(d,J=2.2Hz,1H),7.64(d,J=8.4Hz, 1H),7.60(d,J=8.7Hz,1H),7.48(s,1H),7.28–7.25(m,2H),7.18–7.15(m,3H), 7.02–6.97(m,4H),6.90(d,J=1.8Hz,1H),6.81(dd,J=8.6,2.1Hz,1H),6.47(d, J=8.9Hz,1H),5.57(t,J=5.6Hz,1H),5.05(dd,J=12.7,5.5Hz,1H),4.28–4.23(m ,1H),4.15(d,J=5.9Hz,2H),3.59–3.57(m,1H),3.52–3.49(m,2H),3.43–3.37( m,2H),3.21(s,4H),3.17–3.14(m,1H),2.91–2.85(m,1H),2.68–2.63(m,1H),2. 59–2.56(m,5H),2.41(d,J=6.9Hz,2H),2.18–2.14(m,1H),2.02–1.99(m,1H),1 .90(d,J=10.4Hz,2H),1.81–1.76(m,3H),1.31–1.27(m,2H),1.13–1.07(m,2H). 13 C NMR(151MHz,DMSO)δ173.29,170.63,168.20,167.71,159.72,157.29,153.57, 152.35,150.61,141.80,134.49,131.98,128.50,127.16,126.71,125.44,119. 59,115.96,115.84,115.73,105.93,94.46,61.37,53.56,53.39,52.68,49.15 ,48.14,47.69,43.94,35.99,31.78,31.47,30.67,29.74,22.73.HRMS(ESI)for C 48 H 53 N 10 O5[M+H] + ,calcd:849.4195,found:849.4200.
[0239] Example 14: Preparation of compound zlc-6-1
[0240] The synthesis method is shown in Example 1.
[0241] 1 H NMR (600MHz, DMSO-d6) δ11.06 (s, 1H), 8.29 (d, J = 2.2Hz, 1H), 7.64 (d, J = 8.4Hz, 1H),7.60(d,J=8.5Hz,1H),7.48(s,1H),7.28–7.25(m,2H),7.18–7.15(m,3H), 7.02–6.97(m,4H),6.91(d,J=1.7Hz,1H),6.82(dd,J=8.6,2.0Hz,1H),6.47(d, J=8.9Hz,1H),5.58–5.56(m,1H),5.05(dd,J=12.7,5.5Hz,1H),4.28–4.24(m,1 H),4.15(d,J=5.8Hz,2H),3.60–3.57(m,1H),3.53–3.49(m,2H),3.43–3.39(m, 2H),3.21(s,4H),3.17–3.15(m,1H),2.91–2.85(m,1H),2.67–2.64(m,1H),2.5 9–2.52(m,5H),2.42(d,J=7.0Hz,2H),2.18–2.15(m,1H),2.02–1.96(m,1H),1. 90(d,J=10.3Hz,2H),1.81–1.76(m,3H),1.31–1.29(m,2H),1.13–1.07(m,2H). 13 C NMR(151MHz,DMSO)δ173.29,170.63,168.20,167.71,159.72,157.29,153.58, 152.35,150.61,141.80,134.49,131.98,128.50,127.16,126.71,125.45,119. 59,115.96,115.84,115.73,105.93,94.46,61.37,53.57,53.39,52.68,49.15 ,48.14,47.69,43.94,35.99,31.78,31.46,30.67,29.74,22.56.HRMS(ESI)for C 48 H 53 N 10 O5[M+H] + ,calcd:849.4195,found:849.4191.
[0242] Example 15: Preparation of compound zlc-6-35
[0243] The synthesis method is shown in Example 1.
[0244] 1 H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.29(d,J=2.2Hz,1H),7.68(d,J=8.5Hz,1H),7.60(d,J=8.9Hz,1H),7.47(s,1H),7.36–7.34(m,1 H),7.28–7.25(m,3H),7.18–7.14(m,3H),6.95(d,J=8.5Hz,2H),6.47–6.45(m,3H),5.48–5.47(m,1H),5.07(dd,J=12.8,5.4Hz,1H),4. 27–4.23(m,1H),4.14(d,J=5.9Hz,2H),3.97(m,2H),3.54–3.50(m,2H),3.45(s,4H),3.00–2.95(m,1H),2.64(d,J=7.3Hz,2H),2.61–2. 57(m,2H),2.54–2.52(m,5H),2.03–1.99(m,1H),1.90(d,J=10.4Hz,2H),1.75(d,J=11.6Hz,2H),1.31–1.27(m,2H),1.11–1.05(m,2H). 13 C NMR(151MHz,DMSO)δ172.82,170.09,167.57,166.99,159.25,156.92,155 .24,153.11,150.90,141.29,133.87,131.44,128.05,126.70,126.49,12 4.91,119.13,118.35,117.85,111.48,107.93,94.00,56.11,52.87,52.3 4,48.78,46.88,43.48,31.30,30.98,30.20,29.03,27.22.HRMS(ESI)for C 47 H 51 N 10 O5[M+H] + ,calcd:835.4038,found:835.4045.
[0245] Example 16: Preparation of compound zlc-6-37
[0246] The synthesis method is shown in Example 1.
[0247] 1 H NMR (600MHz, DMSO-d6) δ11.07(s,1H),8.29(d,J=2.2Hz,1H),7.64(d,J=8.3Hz ,1H),7.60(d,J=7.8Hz,1H),7.47(s,1H),7.28–7.25(m,2H),7.18–7.14(m,3H) ,6.99–6.94(m,4H),6.79(s,1H),6.65–6.63(dd,J=8.4,1.9Hz,1H),6.47–6.4 6(m,1H),5.54(t,J=5.7Hz,1H),5.05(dd,J=12.8,5.4Hz,1H),4.28–4.22(m,1H ),4.14(d,J=5.9Hz,2H),4.10(s,4H),3.71(d,J=12.1Hz,2H),3.36(m,2H),2. 90–2.84(m,1H),2.67–2.63(m,2H),2.59–2.56(m,1H),2.56–2.52(m,2H),2.48 –2.46(m,2H),2.02–1.98(m,1H),1.90(d,J=10.3Hz,2H),1.76(d,J=11.9Hz,4H ),1.45–1.38(m,1H),1.33–1.26(m,2H),1.24–1.17(m,4H),1.13–1.06(m,2H). 13 C NMR (151MHz, DMSO) δ173.28,170.57,167.96,167.64,159.72,157.30,155. 34,153.57,151.04,141.79,134.26,131.92,128.50,128.23,127.15,126.7 1,125.28,119.59,117.46,116.27,114.92,105.17,94.46,64.77,61.69,53 .38,49.19,48.61,43.94,34.69,31.77,31.45,30.67,22.67.HRMS(ESI)for C 50 H 55 N 10 O5[M+H] + ,calcd:875.4351,found:875.4349.
[0248] Example 17: Preparation of compound zlc-6-38
[0249] The synthesis method is shown in Example 1.
[0250] 1 H NMR (600MHz, DMSO-d6) δ11.14(s,1H),8.29(d,J=2.2Hz,1H),7.92(d,J=2.9Hz,3H),7.60(d,J=8.9Hz,1H),7.47(s,1H),7.28–7.25 (m,2H),7.18–7.15(m,3H),7.02–6.99(s,4H),6.46(d,J=8.9Hz,1H),5.57(t,J=5.8Hz,1H),5.16(dd,J=12.9,5.4Hz,1H),4.28–4. 23(m,1H),4.14(d,J=6.0Hz,2H),3.68(s,2H),3.39–3.36(m,1H),3.27–3.22(m,4H),2.92–2.86(m,1H),2.72–2.69(m,4H),2.62–2 .59(m,1H),2.56–2.53(m,1H),2.08–2.04(m,1H),1.93–1.87(m,2H),1.76(d,J=11.4Hz,2H),1.32–1.26(m,2H),1.12–1.06(m,2H). 13 C NMR (151MHz, DMSO) δ172.75,169.76,166.50,166.42,156.80,153.11,150. 14,141.33,137.58,131.83,131.52,130.28,128.77,128.32,128.03,126.7 0,126.24,125.74,123.83,119.13,115.55,93.99,90.49,83.72,52.91,51 .46,49.12,47.62,46.75,43.47,31.31,30.92,30.20,21.93.HRMS(ESI)for C 46 H 46 N9O5[M+H] + ,calcd:804.3616,found:804.3623.
[0251] Example 18: Preparation of compound zlc-6-42
[0252] The synthesis method is shown in Example 1.
[0253] 1H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.29(d,J=2.4,1H),7.68(d,J=8.5Hz,1H),7.60(d,J=9.0Hz,1H),7.47(s,1H),7.34(d,J=2.2Hz,1H),7.28–7. 25(m,3H),7.18–7.15(m,3H),6.99–6.96(m,4H),6.47(d,J=8.9Hz,1H),5. 55(t,J=6.0Hz,1H),5.07(dd,J=12.8,5.4Hz,1H),4.28–4.23(m,1H),4.15 (d,J=6.1Hz,2H),3.74(d,J=11.8Hz,2H),3.44(s,4H),3.42–3.36(m,4H), 2.90–2.85(m,1H),2.72–2.68(m,2H),2.61–2.54(m,2H),2.23(d,J=7.2Hz ,2H),2.03–1.99(m,1H),1.90(d,J=11.6Hz,2H),1.84(d,J=12.1Hz,2H),1 .77–1.72(m,3H),1.31–1.28(m,2H),1.25–1.20(m,4H),1.13–1.07(m,2H). 13 C NMR(151MHz,DMSO)δ172.83,170.10,167.58,167.00,159.26,156.85,155.27, 153.11,150.62,141.33,133.87,131.46,128.04,127.74,126.70,126.25,124. 92,119.14,118.32,117.78,115.80,107.89,94.00,63.74,52.91,52.76,48.78 ,48.12,46.96,43.48,32.44,31.32,30.99,30.32,30.21,22.19.HRMS(ESI)for C 49 H 55 N 10 O5[M+H] + ,calcd:863.4351,found:863.4357.
[0254] Example 19: Preparation of compound zlc-6-101
[0255] The synthesis method is shown in Example 1.
[0256] 1 H NMR (600MHz, DMSO-d6) δ11.07(s,1H),8.29(d,J=2.1Hz,1H),7.66(d,J=8.5Hz,1H),7.60(d,J=8.7Hz,1H),7.48(s,1H),7 .32(s,1H),7.28–7.23(m,3H),7.18–7.15(m,3H),6.99(s,4H),6.50–6.43(m,1H),5.54–5.52(m,1H),5.06(dd,J=12.8,5 .5Hz,1H),4.28–4.24(m,1H),4.15(d,J=5.8Hz,2H),3.51(s,6H),3.22(s,4H),2.91–2.85(m,1H),2.60–2.57(m,2H),2.0 3–1.99(m,1H),1.91(d,J=10.6Hz,2H),1.77(d,J=10.4Hz,2H),1.63–1.59(m,8H),1.33–1.28(m,2H),1.14–1.07(m,2H). 13 C NMR(151MHz,DMSO)δ172.83,170.14,167.67,167.00,159.25,156.84,15 4.97,153.11,141.31,134.04,131.46,128.05,127.66,126.70,126.26,1 25.00,119.13,117.35,115.47,107.50,94.00,69.79,52.90,48.74,43.4 8,42.89,34.82,34.12,31.31,30.99,30.21,29.14,22.21.HRMS(ESI)for C 48 H 52 N9O5[M+H] + ,calcd:834.4086,found:834.4073.
[0257] Example 20: Preparation of compound zlc-6-102
[0258] The synthesis method is shown in Example 1.
[0259] 1H NMR (600MHz, DMSO-d6) δ11.06(s,1H),8.30(d,J=2.2Hz,1H),7.65(d,J=8.4Hz,1H),7.60(d,J=8.2Hz,1H),7.48–7.45(m,1H),7.28–7.26(m,2 H),7.19–7.15(m,3H),7.02–6.99(m,4H),6.96(s,1H),6.83(dd,J=8.6,1.6Hz,1H),6.47(d,J=8.9Hz,1H),5.52(t,J=5.6Hz,1H),5.07–5.04( m,1H),4.29–4.24(m,1H),4.15(d,J=5.9Hz,2H),3.53–3.50(m,2H),3. 37(m,4H),3.24–3.21(m,1H),2.91–2.85(m,1H),2.61–2.52(m,4H),2. 02–1.98(m,1H),1.97–1.95(m,2H),1.91(d,J=10.7Hz,2H),1.77(d,J= 10.3Hz,2H),1.73–1.66(m,4H),1.33–1.27(m,2H),1.13–1.07(m,2H). 13 C NMR(151MHz,DMSO)δ172.83,170.16,167.74,167.26,159.25,156.82,153.12 ,152.06,150.42,141.28,134.02,131.48,128.05,127.83,126.70,126.27,1 24.94,119.13,115.80,115.54,115.22,105.58,94.00,57.28,52.90,48.69, 46.32,45.44,43.49,35.02,34.06,31.31,31.00,30.22,22.26.HRMS(ESI)for C 47 H 50 N9O5[M+H] + ,calcd:820.3929,found:820.3933.
[0260] Example 21: Preparation of compound zlc-6-103
[0261] The synthesis method is shown in Example 1.
[0262] 1H NMR (600MHz, DMSO-d6) δ11.07(s,1H),8.30(d,J=2.2Hz,1H),7.65(d,J=8.3Hz,1H),7.60(d,J=8.1Hz,1H),7.48(s,1H),7.28–7.26(m, 2H),7.19–7.15(m,3H),7.06–7.03–6.99(m,4H),6.80(d,J=1.8Hz,1H),6.67(dd,J=8.4,2.0Hz,1H),6.47(d,J=8.8Hz,1H),5.56(t,J= 5.6Hz,1H),5.05(dd,J=12.8,5.5Hz,1H),4.29–4.23(m,1H),4.15(d,J=5.8Hz,1H),3.83(m,4H),3.43–3.41(m,2H),3.22(m,3H),2.91 –2.85(m,1H),2.59–2.53(m,2H),2.02–1.89(m,1H),1.91–1.89(m,6H),1.77(d,J=10.1Hz,2H),1.33–1.27(m,2H),1.13–1.07(m,2H). 13 C NMR (151MHz, DMSO) δ172.83,170.12,167.53,167.21,159.26,156.83,155.20 ,153.12,150.21,141.33,133.86,131.53,128.04,126.71,126.26,124.87,1 22.51,119.14,116.69,115.95,114.18,104.42,94.00,60.78,52.92,48.73, 45.32,43.49,34.65,34.21,31.32,30.99,30.21,22.23,20.45.HRMS(ESI)for C 46 H 48 N9O5[M+H] + ,calcd:806.3773,found:806.3767.
[0263] Example 22: Preparation of compound zlc-7-36
[0264] The synthesis method is shown in Example 1.
[0265] 1H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.29(d,J=2.2Hz,1H),7.60–7.58(m,2H),7.51–7.44(m,1H),7.29–7.25(m,2H),7.18–7.15(m, 3H),7.01–6.97(m,4H),6.91(d,J=7.6Hz,1H),6.46(d,J=8.9Hz,1H),5.57(t,J=5.6Hz,1H),5.06(dd,J=12.9,5.4Hz,1H),4.30–4.24( m,3H),4.15(d,J=5.8Hz,2H),3.87–3.85(m,2H),3.53–3.44(m,1H),3.19(s,4H),3.04–3000(m,1H),2.90–2.84(m,1H),2.67(d,J=6. 8Hz,2H),2.61–2.51(m,6H),2.03–1.99(m,1H),1.90(d,J=10.5Hz,2H),1.76(d,J=10.6Hz,2H),1.31–1.27(m,2H),1.12–1.07(m,2H). 13 C NMR (151MHz, DMSO) δ172.80,170.02,166.84,166.43,159.26,156.83,154.43,153. 11,152.79,144.21,144.13,141.34,131.52,129.38,128.23,128.04,126.70,119. 14,118.30,115.43,111.33,111.19,107.95,94.00,61.57,57.75,52.93,52.83,48 .94,47.64,43.48,31.32,30.97,30.21,27.85,22.17,22.08,13.99.HRMS(ESI)for C 47 H 50 FN 10 O5[M+H] + ,calcd:853.3944,found:853.3956.
[0266] Example 23: 3-Benzyl-1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)oxy)acetyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ9069)
[0267] Step 1: Preparation of tert-butyl 4-(4-(((1r,4r)-4-aminocyclohexyl)amino)phenyl)piperazine-1-carboxylate (Compound 3)
[0268] Potassium phosphate (31 g, 146 mmol), trans-cyclohexane-1,4-diamine 2 (29.3 g, 256.4 mmol), tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate 1 (25 g, 73.26 mmol), CuI (1.39 g 7.3 mmol) and D-proline (843 mg, 7.3 mmol) were dissolved in anhydrous DMSO (500 mL). The resulting suspension was then protected by argon and replaced three times. The reaction mixture was then heated and stirred at 100 ° C for 10 hours, filtered through celite, and the filter residue was washed with ethyl acetate 2-3 times. After evaporation of the filtrate under reduced pressure, it was purified by silica gel column to obtain 12 g of the target compound as an off-white solid (yield 44%). 1 H NMR (400MHz, DMSO-d6) δ6.74(d,J=8.8Hz,2H),6.49(d,J=8.9Hz,2H),4.88(d,J=8.2Hz,1H),3.42(t,J=5.1Hz,4H),3.03(s,1H),2.83(t,J=5.1H z,4H),2.76(s,1H),1.95(d,J=12.8Hz,2H),1.85(d,J=12.4Hz,2H),1.41(s,9H),1.26(q,J=10.9Hz,2H),1.11(q,J=11.6Hz,2H).HRMS(ESI)for C 21 H 34 N4O2[M+H] + ,calcd:375.2755,found:375.2739.
[0269] Step 2: Preparation of tert-butyl 4-(4-(((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)amino)phenyl)piperazine-1-carboxylate (Compound 5)
[0270] To a solution of tert-butyl 4-(4-(((1r,4r)-4-aminocyclohexyl)amino)phenyl)piperazine-1-carboxylate 3 (9 g, 24 mmol) in DMF (40 mL) was added 2-chloroquinazoline 4 (4 g, 24 mol) and Cs2CO3 (9.4 g, 28.9 mol). The mixture was stirred at room temperature for 15 minutes and then heated to 60°C for 40 minutes. The reaction solution was then filtered, and the filtrate was concentrated by rotary evaporation under reduced pressure. Purification by column chromatography afforded 11.2 g of an off-white solid (93% yield).1 H NMR(400MHz, DMSO-d6)δ9.09(s,1H),7.77(d,J=8.0Hz,1H),7.67(t,J=7.7Hz,1H),7.45 (d,J=8.5Hz,1H),7.29(d,J=8.0Hz,1H),7.20(t,J=7.4Hz,1H),6.76(d,J=8.2Hz,2H),6 .52(d,J=8.3Hz,2H),4.95(s,1H),3.86(d,J=9.8Hz,1H),3.43(t,J=5.0Hz,4H),3.18–3 .01(m,1H),2.84(s,4H),2.01(d,J=11.6Hz,4H),1.50–1.32(m,11H),1.30–1.15(m,2H).
[0271] Step 3: Preparation of tert-butyl 4-(4-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazine-1-carboxylate (Compound 7)
[0272] Tert-butyl 4-(4-(((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)amino)phenyl)piperazine-1-carboxylate 5 (11.2 g, 22.25 mmol), DIPEA (8.6 g, 66.76 mmol), and benzyl isocyanate 6 (8.9 g, 66.76 mmol) were dissolved in 15 mL of DMF. The mixture was stirred at 95°C for 4 hours. The solvent was removed under reduced pressure, and the product was purified by column chromatography to afford 10.2 g of a white solid (72% yield). 1 H NMR (400MHz, DMSO-d6) δ9.05(s,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.8Hz,1H),7.40(d,J=8.8 Hz,1H),7.31–7.22(m,3H),7.21–7.13(m,4H),7.08–6.98(m,4H),5.58(t,J=6.1Hz,1H),4.28(t, J=12.3Hz,1H),4.16(d,J=5.8Hz,2H),3.58(s,1H),3.47(t,J=5.1Hz,4H),3.18(t,J=5.2Hz,4H), 1.96(d,J=12.0Hz,2H), 1.79(d,J=12.3Hz,2H), 1.50–1.33(m,12H), 1.13(q,J=13.5,12.5Hz,2H).
[0273] Step 4: Preparation of 3-benzyl-1-(4-(piperazin-1-yl)phenyl)-1-(1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound 8)
[0274] Tert-butyl 4-(4-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazine-1-carboxylate 7 (7.3 g, 11.5 mmol) was dissolved in DCM (20 mL), TFA (10 mL) was added, and the mixture was stirred and refluxed at 50° C. overnight. The reaction mixture was then concentrated under reduced pressure, and the resulting transparent oily substance (4.3 g, 70% yield) was purified by column chromatography. 1 H NMR (400MHz, DMSO-d6) δ9.05(s,1H),7.74(dd,J=8.0,1.5Hz,1H),7.63(t,J=8.5Hz,1H),7.41(d,J=8.5 Hz,1H),7.31–7.21(m,3H),7.21–7.13(m,4H),7.00(q,J=9.1Hz,4H),5.56(t,J=6.1Hz,1H),4.28(tt,J= 12.1,3.7Hz,1H),4.16(d,J=6.0Hz,2H),3.65–3.53(m,1H),3.11(dd,J=6.3,3.7Hz,4H),2.84(t,J=5.0 Hz, 4H), 1.96 (d, J = 10.9Hz, 2H), 1.79 (d, J = 10.8Hz, 2H), 1.41 (q, J = 13.1Hz, 2H), 1.13 (q, J = 13.0Hz, 2H).
[0275] Step 5: Preparation of 3-benzyl-1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)oxy)acetyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl) (Compound YJZ9069)
[0276] 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid 9 (39.9 mg, 0.12), HATU (45.1 mg, 0.12 mmol), DIPEA (21.3 mg, 0.16 mmol), and compound 8 (59 mg, 0.11 mmol) were dissolved in DMF (6 mL). The mixture was stirred at room temperature for 15 minutes, then the reaction solution was rotary evaporated under reduced pressure and purified by silica gel column chromatography to obtain the title compound as a white solid (70 mg, 75% yield).
[0277] 1 H NMR(400MHz,DMSO-d6)δ11.12(s,1H),9.05(s,1H),7.79(t,J=7.9Hz,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.8Hz,1H),7.46(d,J=7.2Hz,1H),7.39(t,J=8.1Hz,2H),7.27(q,J=9.9,8.7Hz,3H),7.22–7.13(m,4H),7.11–7.02(m,4H),5.60(t,J=6.0Hz,1H),5.26(s,2H),5.12(dd,J=12.8,5.4Hz,1H),4.27(d,J=12.4Hz,1H),4.17(d,J=6.0Hz,2H),3.62(s,4H),3.31(s,1H),3.24(s,2H),2.96–2.82(m,1H),2.65–2.53(m,2H),2.10–2.00(m,1H),1.97(d,J=10.8Hz,2H),1.80(d,J=11.8Hz,2H),1.41(q,J=12.5Hz,2H),1.13(q,J=12.3Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.31,170.43,167.29,165.76,165.61,162.50,157.33,156.06,150.34,141.73,137.09,134.48,133.55,132.13(2C),129.17,128.52(3C),128.32,127.17(4C),126.75,122.21,120.67,119.95,116.60,116.40(2C),116.00,66.57,53.54,49.23,49.13,48.29,48.16,44.33,43.94,41.69,40.043,31.75,31.40,30.87(2C),22.46.HRMS(ESI)for C 47 H 47 N9O7[M+H] + ,calcd:850.36712,found:850.3646.HPLC analysis:MeOH-H2O(80:20),12.08min,97.4%purity.
[0278] Example 24: 3-Benzyl-1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)oxy)acetyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1090)
[0279] The synthesis method is similar to that shown in Example 23.
[0280] 1 H NMR (400MHz, DMSO-d6) δ11.11(s,1H),9.05(s,1H),7.85(d,J=8.3Hz,1H),7.74(d,J=8.3Hz,1H),7.63(t,J=7.9Hz,1H),7.48(d,J=2.3Hz, 1H),7.43–7.35(m,2H),7.32–7.24(m,3H),7.23(d,J=8.2Hz,1H),7.21–7.13(m,4H),7.11–7.00(m,4H),5.60(t,J=5.8Hz,1H),5.21(s,2H) ,5.12(dd,J=12.9,5.4Hz,1H),4.27(t,J=12.3Hz,1H),4.17(d,J=6.0Hz,2H),3.70–3.52(m,5H),3.31(s,2H),3.24(s,2H),2.95–2.83(m, 1H),2.65–2.54(m,2H),2.10–2.01(m,1H),1.97(d,J=11.4Hz,2H),1.80(d,J=11.9Hz,2H),1.41(q,J=12.4Hz,2H),1.14(q,J=12.0Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.30,170.42,167.42,167.27,165.69,164.15,162.50,157.32,15 0.32,141.74,134.47,134.17,132.13(2C),129.19,128.52(3C),128.32,127.17(4C),126.7 4,125.65,123.70,122.21,121.69,119.95,116.39(2C),109.58,66.60,53.54,49.45,49.13 ,48.34,48.16,44.28,43.94,41.64,40.44,31.75,31.41,30.87(2C),22.52.HRMS(ESI)forC47 H 47 N9O7[M+H] + ,calcd:850.36712,found:850.3633.HPLC analysis:MeOH-H2O(75:25),6.96min,95.0%purity.
[0281] Example 25: 3-Benzyl-1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindol-5-yl)oxy)acetyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1094)
[0282] The synthesis method is similar to that shown in Example 23.
[0283] 1 H NMR (400MHz, DMSO-d6) δ10.98(s,1H),9.05(s,1H),7.74(d,J=7.9Hz,1H),7.63(t,J=7.7Hz,1H),7.51(d,J=8.2Hz,1H) ,7.40(d,J=8.5Hz,1H),7.31–7.21(m,5H),7.21–7.13(m,4H),7.08–7.00(m,4H),5.60(t,J=5.9Hz,1H),5.11(dd,J=13. 2,5.1Hz,1H),5.03(s,2H),4.43–4.21(m,3H),4.16(d,J=6.0Hz,2H),3.71–3.53(m,5H),3.30(s,2H),3.23(s,2H),2.96 –2.84(m,1H),2.68–2.53(m,2H),2.04–1.90(s,3H),1.80(d,J=12.1Hz,2H),1.41(q,J=12.3Hz,2H),1.20–1.06(m,2H). 13C NMR(151MHz,DMSO-d6)δ173.41,171.47,168.57,166.31,162.50,158.74,157.33,150.34,1 41.75,134.97,134.48,133.27,132.11(2C),129.16,128.52(3C),128.32,127.16(4C),126 .74,124.92,122.21,120.65,119.95,116.38(2C),107.67,66.52,53.54,52.21(2C),48.45 ,48.18,47.28,44.44,43.93,41.63,40.43,31.74,31.66,30.86(2C),22.92.HRMS(ESI)forC 47 H 49 N9O6[M+H] + ,calcd:836.38786,found:836.3843.HPLC analysis:MeOH-H2O(75:25),6.33min,95.6%purity.
[0284] Example 26: 3-Benzyl-1-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)glycine)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1091)
[0285] The synthesis method is similar to that shown in Example 23.
[0286] 1H NMR(400MHz,DMSO-d6)δ11.06(s,1H),9.05(s,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.5Hz,1H),7.59(d,J=8.3Hz,1H),7.40(d,J=8.5Hz,1H),7.31–7.25(dd,J=8.5,6.5Hz,2H),7.23(d,J=8.2Hz,1H),7.21–7.11(m,6H),7.09–9.00(m,5H),5.60(t,J=5.6Hz,1H),5.05(dd,J=12.9,5.5Hz,1H),4.27(t,J=12.3Hz,1H),4.22(d,J=5.1Hz,2H),4.16(d,J=6.2Hz,2H),3.68(s,4H),3.58(s,1H),3.30(s,2H),3.24(s,2H),2.93–2.81(m,1H),2.62–2.53(m,2H),2.45–1.89(m,3H),1.80(d,J=12.1Hz,2H),1.41(q,J=12.2Hz,2H),1.14(d,J=13.3Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.34,170.66,168.23,167.70,167.35,162.50,159.29,157.33,154.52,152.04,150.36,141.74,134.47,132.12(2C),129.17,128.52(4C),128.32,127.17(4C),126.74,125.28,122.21,119.95,117.14,116.39(2C),53.54,49.11(2C),48.40,48.18,44.73,44.30,43.94,41.83,40.43,31.75,31.44,30.87(2C),22.69.HRMS(ESI)for C 47 H 48 N 10 O6[M+H] + ,calcd:849.38311,found:849.3803.HPLC analysis:MeOH-H2O(75:25),7.47min,96.8%purity.
[0287] Example 27: 3-Benzyl-1-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindol-5-yl)glyceryl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1095)
[0288] The synthesis method is similar to that shown in Example 23.
[0289] 1 H NMR(400MHz,DMSO-d6)δ10.95(s,1H),9.05(s,1H),7.74(d,J=7.3Hz,1H),7 .63(t,J=7.8Hz,1H),7.40(d,J=8.5Hz,1H),7.28(t,J=7.6Hz,3H),7.23(d, J=8.0Hz,1H),7.18(t,J=7.1Hz,4H),7.10–6.99(m,5H),6.94(d,J=2.2Hz,1 H),5.97(t,J=5.1Hz,1H),5.60(t,J=6.0Hz,1H),5.08(dd,J=13.3,5.1Hz,1H ),4.35–4.23(d,J=16.5Hz,2H),4.19–4.12(m,3H),4.07(d,J=5.1Hz,2H),3 .69(d,J=17.3Hz,4H),3.59(s,1H),3.31(s,2H),3.23(s,2H),2.96–2.84(m ,1H),2.69–2.55(m,2H),2.43–2.30(m,1H),1.97(d,J=11.7Hz,2H),1.80(d ,J=11.7Hz,2H),1.41(q,J=12.6,12.2Hz,2H),1.14(q,J=13.5,11.1Hz,2H). 13C NMR(151MHz,DMSO-d6)δ173.41,171.47,168.57,166.31,162.50,158.74,157.33,150.34,1 41.75,134.97,134.48,133.27,132.11(2C),129.16,128.52(3C),128.32,127.16(4C),126. 74,124.92,122.21,120.65,119.95,116.38(2C),107.67,66.52,53.54,52.21,49.11,48.4 5,48.18,47.28,44.44,43.93,41.63,40.43,31.75,31.66,30.86(2C),22.92.HRMS(ESI)for C 47 H 50 N 10 O5[M+H] + ,calcd:835.40384,found:835.4012.HPLC analysis:MeOH-H2O(75:25),6.70min,95.8%purity.
[0290] Example 28: 3-Benzyl-1-(4-(4-(1-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)azetidine-3-carbonyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1093)
[0291] The synthesis method is similar to that shown in Example 23.
[0292] 1H NMR(400MHz,DMSO-d6)δ11.07(s,1H),9.05(s,1H),7.74(d,J=7.9Hz,1H),7.66(d,J=8.3Hz,1H),7.62(t,J=8.0Hz,1H),7.40(d,J=8.5Hz,1H),7.31–7.25(m,2H),7.24(d,J=8.2Hz,1H),7.21–7.13(m,4H),7.10–7.00(m,4H),6.85(d,J=2.1Hz,1H),6.71(dd,J=8.4,2.2Hz,1H),5.58(t,J=6.2Hz,1H),5.06(dd,J=12.9,5.5Hz,1H),4.34–4.22(m,3H),4.22–4.08(m,4H),4.05–3.94(m,1H),3.66(s,2H),3.58(s,1H),3.51(s,2H),3.29–3.16(m,4H),2.94–2.82(m,1H),2.70–2.52(m,2H),2.06–1.90(m,3H),1.80(d,J=11.9Hz,2H),1.41(q,J=12.3Hz,2H),1.19–1.06(m,2H). 13 C NMR(151MHz,DMSO-d6)δ173.34,170.59,169.88,167.92,167.65,162.50,157.33,155.46,150.39,141.70,134.49,134.25,132.11(2C),129.20,128.53(3C),128.32,127.17(4C),126.76,125.33,122.22,119.95,117.67,116.46(2C),114.80,105.02,54.09(2C),53.53,49.18(2C),48.53,48.20,44.89,43.93,41.79,40.40,31.74,31.68,31.42,30.87(2C),22.65.HRMS(ESI)for C 49 H 50 N 10 O6[M+H] + ,calcd:875.39876,found:875.3958.HPLC analysis:MeOH-H2O(75:25),8.69min,97.7%purity.
[0293] Example 29: 3-Benzyl-1-(4-(4-((E)-3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)acryloyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1114)
[0294] The synthesis method is similar to that shown in Example 23.
[0295] 1 H NMR (400MHz, DMSO-d6) δ11.15(s,1H),9.05(s,1H),8.48(s,1H),8.19(d,J=7.8Hz,1H),7.96(d,J=7.7Hz,1H),7.74(d,J=7.9Hz,1H), 7.71(s,2H),7.63(t,J=7.8Hz,1H),7.39(d,J=8.6Hz,1H),7.31–7.21(m,3H),7.21–7.13(m,4H),7.07(s,4H),5.59(t,J=6.4Hz,1H),5 .19(dd,J=13.0,5.4Hz,1H),4.27(t,J=11.9Hz,1H),4.17(d,J=5.8Hz,2H),3.95(s,2H),3.76(s,2H),3.58(s,1H),2.97–2.83(m,1H), 2.69–2.56(m,2H),2.13–2.04(m,2H),1.96(d,J=11.9Hz,2H),1.80(d,J=11.9Hz,2H),1.41(q,J=12.1Hz,2H),1.16(q,J=12.1Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.26,170.31,167.43,167.23,164.45,162.49,157.29,150.37,142 .28,141.79,140.14,135.37,134.45,132.59,132.13(2C),131.66,129.21,128.51(3C),128. 31,127.18(4C),126.72,124.38,122.87,122.63,122.18,119.95,116.38(2C),53.54,49.57( 2C),48.90,48.27,45.38,43.95,42.19,40.50,31.76,31.41,30.88(2C),22.45.HRMS(ESI)for C48 H 47 N9O6[M+H] + ,calcd:846.37221,found:846.3687.HPLC analysis:MeOH-H2O(75:25),14.00min,99.3%purity.
[0296] Example 30: 3-Benzyl-1-(4-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)benzoyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1130)
[0297] The synthesis method is similar to that shown in Example 23.
[0298] 1 H NMR (400MHz, DMSO-d6) δ11.15(s,1H),9.05(s,1H),8.30–8.21(m,2H),8.03(d,J=7.7Hz,1H),7.97(d,J=7.9Hz,1H),7.92(s,1H),7.75(d,J=8 .1Hz,1H),7.68–7.60(m,2H),7.55(d,J=7.6Hz,1H),7.40(d,J=8.5Hz,1H),7.31–7.23(m,3H),7.21–7.13(m,4H),7.11–6.98(m,4H),5.57(t, J=6.8Hz,1H),5.19(dd,J=12.6,5.3Hz,1H),4.28(t,J=12.1Hz,1H),4.16(d,J=5.7Hz,2H),3.82(s,1H),3.57(s,4H),3.25(s,4H),2.97–2.84 (m,1H),2.69–2.58(m,2H),2.14–2.04(m,1H),1.96(d,J=11.4Hz,2H),1.80(d,J=12.0Hz,2H),1.41(q,J=12.1Hz,2H),1.14(q,J=12.1Hz,2H). 13C NMR(151MHz,DMSO-d6)δ173.26,170.33,169.02,167.42,167.39,162.48,157.27,150.37,146.31,14 1.76,138.78,137.40,134.44,133.72,132.81,132.13(2C),130.67,129.99,129.25,128.96,128.51( 3C),128.31,127.93,127.17(4C),126.72,126.26,124.58,122.21,122.18,119.96,116.46(2C),53.5 3,49.57(2C),49.12,48.28,47.52,43.95,40.51,31.75,31.42(2C),30.88(2C),22.47.HRMS(ESI)for C 52 H 49 N9O6[M+H] + ,calcd:896.38786,found:896.3845.HPLC analysis:MeOH-H2O(75:25),19.82min,98.9%purity.
[0299] Example 31: 3-Benzyl-1-(4-(4-(1-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)-1-pyrazole-3-carbonyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1131)
[0300] The synthesis method is similar to that shown in Example 23.
[0301] 1H NMR(400MHz,DMSO-d6)δ11.16(s,1H),9.19(s,1H),9.05(s,1H),8.49(s,1H),8.44(d,J=8.3Hz,1H),8.16(s,1H),8.09(d,J=8.2Hz,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.8Hz,1H),7.39(d,J=8.6Hz,1H),7.31–7.21(m,3H),7.21–7.13(m,4H),7.11–6.97(m,4H),5.60(t,J=6.2Hz,1H),5.21(dd,J=13.0,5.4Hz,1H),4.29(t,J=12.2Hz,1H),4.17(d,J=6.0Hz,2H),3.83(s,4H),3.58(s,1H),3.31(s,4H),2.98–2.85(m,1H),2.69–2.57(m,2H),2.15–2.04(m,1H),1.97(d,J=12.6Hz,2H),1.80(d,J=11.9Hz,2H),1.41(q,J=12.9,12.4Hz,2H),1.14(q,J=12.9,12.1Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.24,170.29,166.93,166.88,162.48,162.33,157.29,150.33,144.34,143.30,141.78,134.44,133.77,132.17(2C),130.30,129.21,129.05,128.51(3C),128.31,127.18(4C),126.73,125.67,125.25,124.64,122.17,119.98,119.96,116.32(2C),113.73,53.55,49.66(2C),49.13,48.46,43.96(2C),40.51,31.76,31.41(2C),30.89(2C),22.45. HRMS(ESI)for C 49 H 47 N 11 O6[M+H] + ,calcd:886.37835,found:886.3749.HPLC analysis:MeOH-H2O(75:25),14.54min,96.4%purity.
[0302] Example 32: 3-Benzyl-1-(4-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)oxy)acetyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1078)
[0303] The synthesis method is similar to that shown in Example 23.
[0304] 1 H NMR (400MHz, DMSO-d6) δ9.05(s,1H),7.79(t,J=7.8Hz,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.8Hz,1H),7.47(d,J=7.3Hz,1H),7.39(d,J=8. 4Hz,2H),7.31–7.21(m,3H),7.21–7.13(m,4H),7.10–6.99(s,4H),5.59(t,J=6.0Hz,1H),5.25(s,2H),5.18(dd,J=12.7,5.0Hz,1H),4.28(t,J =10.4Hz,1H),4.17(d,J=6.0Hz,2H),3.67–3.56(m,5H),3.32(s,2H),3 .24(s,2H),3.02(s,3H),3.00–2.88(m,1H),2.81–2.70(m,1H),2.60–2 .54(m,1H),2.06(d,J=9.7Hz,1H),1.97(d,J=11.6Hz,2H),1.80(d,J=11.9Hz,2H),1.42(q,J=12.8,12.4Hz,2H),1.14(q,J=12.3,11.6Hz,2H). 13C NMR(151MHz,DMSO-d6)δ172.28,170.18,167.28,165.76,165.60,162.50,157.33,156.07,150 .34,141.72,137.14,134.48,133.54,132.12(2C),129.17,128.52(3C),128.32,127.17(4C), 126.75,122.21,120.71,119.95,116.58,116.39(2C),116.03,66.61,53.54,49.81,49.13,48 .31,48.15,44.34,43.94,41.70,40.43,31.75,31.55,30.87(2C),27.08,21.67.HRMS(ESI)for C 48 H 49 N9O7[M+H] + ,calcd:864.38277,found:864.3804.HPLC analysis:MeOH-H2O(75:25),9.27min,97.5%purity.
[0305] Example 33: 3-Benzyl-1-(4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)oxy)acetyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-((1-propyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)urea (Compound YJZ9108)
[0306] The synthesis method is similar to that shown in Example 23.
[0307] 1H NMR (400MHz, DMSO-d6) δ11.12(s,1H),8.73(s,1H),7.89(s,1H),7.79(dd,J=8.5,7 .3Hz,1H),7.46(d,J=7.2Hz,1H),7.38(d,J=8.6Hz,1H),7.28(dd,J=8.4,6.4Hz,3H) ,7.21–7.13(m,3H),7.09–7.00(m,4H),5.57(s,1H),5.25(s,2H),5.11(dd,J=12.9, 5.4Hz,1H),4.26(s,1H),4.16(d,J=6.0Hz,2H),4.09(t,J=6.8Hz,2H),3.62(s,4H), 3.51(s,1H),3.30(s,2H),3.24(s,2H),2.96–2.82(m,1H),2.64–2.53(m,2H),2.09–1. 92(m,3H),1.84–1.70(m,4H),1.40(q,J=12.7Hz,2H),1.16–1.03(m,2H),0.76(s,3H).
[0308] Example 34: N-(4-(4-(3-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazin-1-yl)butyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)oxy)acetamide (Compound YJZ9049)
[0309] The synthesis method is similar to that shown in Example 23.
[0310] 1H NMR (400MHz, DMSO-d6) δ11.12(s,1H),9.05(s,1H),7.97(t,J=4.9Hz 1H),7.82(t,J=7.9Hz,1H),7.74(d,J=8.1Hz,1H),7.63(t,J=7.8Hz,1H),7.50(d,J=7.3Hz,1H),7.40(d,J=8.5Hz,2H),7.33–7.21m,4H),7.21–7 .13(m,4H),6.97(d,J=8.5Hz,1H),6.69(s,1H),6.61(d,J=7.6Hz,1H),5 .60(t,J=6.2Hz,1H),5.12(dd,J=13.0,5.4Hz,1H),4.78(s,2H),4.25(t, J=12.4Hz,1H),4.18(d,J=5.9Hz,2H),3.61(d,J=9.3Hz,1H),3.25–3.08 (m,6H),2.96–2.83(m,1H),2.63–2.53(m,2H),2.48–2.44(m,2H),2.32( d,J=6.6Hz,2H),2.03(d,J=12.5Hz,1H),1.97(d,J=12.0Hz,2H),1.83(d ,J=11.8Hz,2H),1.48(s,4H),1.40(t,J=12.4Hz,2H),1.27–1.13(m,4H).
[0311] Example 35: N-(5-(4-(3-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazin-1-yl)pentyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)oxy)acetamide (Compound YJZ9048)
[0312] The synthesis method is similar to that shown in Example 23.
[0313] 1H NMR (400MHz, DMSO-d6) δ11.15(s,1H),9.05(s,1H),7.94(t,J=5.8Hz,1H),7.81(t,J =8.0Hz,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.7Hz,1H),7.50(d,J=7.2Hz,1H),7.4 0(d,J=8.5Hz,2H),7.33–7.24(m,3H),7.22(d,J=8.0Hz,1H),7.20–7.14(m,4H),6.97 (d,J=8.5Hz,1H),6.69(s,1H),6.61(d,J=7.7Hz,1H),5.60(t,J=6.1Hz,1H),5.12(dd ,J=12.9,5.3Hz,1H),4.77(s,2H),4.28(t,J=12.3Hz,1H),4.17(d,J=5.9Hz,2H),3. 61(s,1H),3.20–3.11(m,6H),2.96–2.82(m,1H),2.65–2.53(m,2H),2.47(s,2H),2.2 9(t,J=7.4Hz,2H),2.03(dd,J=11.8,6.3Hz,1H),1.97(d,J=11.6Hz,2H),1.83(d,J=1 1.9Hz, 2H), 1.44 (dd, J=22.9, 10.2Hz, 6H), 1.30 (d, J=7.3Hz, 2H), 1.26–1.14 (m, 2H).
[0314] Example 36: N-(6-(4-(3-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazin-1-yl)hexyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)oxy)acetamide (Compound YJZ9043)
[0315] The synthesis method is similar to that shown in Example 23.
[0316] 1H NMR (400MHz, DMSO-d6) δ11.16(s,1H),9.05(s,1H),7.93(t,J=5.7Hz,1H),7.81(t, J=7.9Hz,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.7Hz,1H),7.50(d,J=7.3Hz,1H), 7.40(d,J=8.5Hz,2H),7.33–7.24(m,3H),7.22(d,J=7.8Hz,1H),7.20–7.14(m,4H) ,6.97(d,J=8.6Hz,1H),6.69(s,1H),6.61(d,J=7.6Hz,1H),5.59(t,J=6.0Hz,1H), 5.12(dd,J=12.9,5.4Hz,1H),4.77(s,2H),4.27(t,J=11.8Hz,1H),4.18(d,J=6.0H z,2H),3.62(s,1H),3.16(t,J=6.2Hz,8H),2.95–2.84(m,1H),2.64–2.54(m,2H),2 .49–2.45(m,2H),2.30(t,J=7.5Hz,2H),2.08–2.00(m,1H),1.97(d,J=12.1Hz,2H) ,1.83(d,J=11.9Hz,2H),1.50–1.35(m,6H),1.33–1.26(m,4H),1.23–1.14(m,2H).
[0317] Example 37: N-(7-(4-(3-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazin-1-yl)heptyl)-2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)oxy)acetamide (Compound YJZ9047)
[0318] The synthesis method is similar to that shown in Example 23.
[0319] 1H NMR (400MHz, DMSO-d6) δ11.15(s,1H),9.05(s,1H),7.92(t,J=5.6Hz,1H),7.81(t, J=7.9Hz,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.7Hz,1H),7.50(d,J=7.3Hz,1H), 7.43–7.35(m,2H),7.28(q,J=8.2,7.8Hz,3H),7.22(d,J=7.8Hz,1H),7.21–7.15(m ,4H),6.97(d,J=8.5Hz,1H),6.69(s,1H),6.61(d,J=7.6Hz,1H),5.76(s,1H),5.60 (t,J=6.1Hz,1H),5.12(dd,J=13.0,5.4Hz,1H),4.77(s,2H),4.25(t,J=12.6Hz,1H ),4.18(d,J=6.0Hz,2H),3.62(s,1H),3.16(dd,J=8.9,5.0Hz,7H),2.95–2.84(m,1 H),2.65–2.54(m,2H),2.48(s,2H),2.30(t,J=7.5Hz,2H),2.08–2.01(m,1H),1.97 (d,J=12.3Hz,2H),1.83(d,J=11.9Hz,2H),1.51–1.34(m,6H),1.33–1.13(m,10H).
[0320] Example 38: 3-Benzyl-1-(3-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)amino)butanoyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ9058)
[0321] The synthesis method is similar to that shown in Example 23.
[0322] 1H NMR (400MHz, DMSO-d6) δ11.08(s,1H),9.05(s,1H),7.74(d,J=7.9Hz,1H),7.61( dt,J=15.9,7.8Hz,2H),7.39(d,J=8.5Hz,1H),7.35–7.24(m,3H),7.22(d,J=7.9 Hz,1H),7.20–7.14(m,5H),7.03–6.97(m,2H),6.72(s,1H),6.70–6.61(m,2H),5.61(t,J=6 .1Hz,1H),5.05(dd,J=12.9,5.4Hz,1H),4.26(t,J=12.1Hz,1H),4.18(d,J=6.0Hz,2H),3.6 8–3.54(m,5H),3.23–3.09(m,4H),2.93–2.82(m,1H),2.62–2.54(m,2H),2.46(t,J=7.0Hz, 2H),2.06–1.93(m,4H),1.89–1.78(m,4H),1.42(q,J=12.4Hz,2H),1.18(q,J=12.0Hz,2H).
[0323] Example 39: 3-Benzyl-1-(3-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)amino)hexyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ9052)
[0324] The synthesis method is similar to that shown in Example 23.
[0325] 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),9.05(s,1H),7.74(d,J=7.7Hz,1H),7.63( t,J=7.7Hz,1H),7.57(dd,J=8.6,7.1Hz,1H),7.39(d,J=8.5Hz,1H),7.35–7.25( m,3H),7.23(d,J=7.8Hz,1H),7.21–7.13(m,4H),7.09(d,J=8.6Hz,1H),7.03–6. 97(m,2H),6.73(s,1H),6.65(d,J=7.5Hz,1H),6.54(t,J=5.9Hz,1H),5.62(t,J= 6.1Hz,1H),5.04(dd,J=12.9,5.3Hz,1H),4.29(t,J=12.0Hz,1H),4.18(d,J=6.0 Hz,2H),3.60(s,5H),3.32–3.26(m,1H),3.16(d,J=19.2Hz,4H),2.93–2.81(m,1 H),2.62–2.53(m,2H),2.37(t,J=7.3Hz,2H),2.06–1.91(m,3H),1.83(d,J=11.8 Hz,2H),1.59(dp,J=14.9,7.2Hz,4H),1.48–1.34(m,4H),1.18(q,J=12.6Hz,2H).
[0326] Example 40: 3-Benzyl-1-(3-(4-(8-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)amino)octyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ9053)
[0327] The synthesis method is similar to that shown in Example 23.
[0328] 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),9.04(s,1H),7.74(d,J=8.0Hz,1H),7.62( t,J=7.7Hz,1H),7.59–7.54(m,1H),7.39(d,J=8.5Hz,1H),7.35–7.25(m,3H),7.2 2(d,J=8.0Hz,1H),7.20–7.14(m,4H),7.08(d,J=8.6Hz,1H),7.04–6.98(m,2H), 6.73(s,1H),6.65(d,J=7.6Hz,1H),6.52(t,J=6.0Hz,1H),5.62(t,J=6.0Hz,1H), 5.04(dd,J=12.9,5.4Hz,1H),4.26(t,J=12.1Hz,1H),4.17(d,J=6.0Hz,2H),3.5 9(s,5H),3.31–3.24(m,1H),3.16(d,J=20.5Hz,4H),2.93–2.81(m,1H),2.62–2.5 3(m,2H),2.35(t,J=7.4Hz,2H),2.06–1.91(m,3H),1.83(d,J=12.0Hz,2H),1.61 –1.48(m,4H),1.41(q,J=12.5Hz,2H),1.36–1.27(m,6H),1.18(q,J=12.5Hz,2H).
[0329] Example 41: 3-Benzyl-1-(3-(4-(10-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)amino)decanoyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ9055)
[0330] The synthesis method is similar to that shown in Example 23.
[0331] 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),9.04(s,1H),7.74(d,J=8.0Hz,1H),7.62 (t,J=7.7Hz,1H),7.57(dd,J=8.6,7.1Hz,1H),7.39(d,J=8.5Hz,1H),7.35–7.2 4(m,3H),7.23(d,J=7.9Hz,1H),7.21–7.13(m,4H),7.07(d,J=8.6Hz,1H),7.04 –6.97(m,2H),6.73(s,1H),6.65(d,J=7.6Hz,1H),6.51(t,J=5.9Hz,1H),5.62(t ,J=5.9Hz,1H),5.05(dd,J=12.9,5.4Hz,1H),4.27(t,J=12.1Hz,1H),4.17(d,J =6.0Hz,2H),3.59(s,5H),3.27(p,J=6.6Hz,2H)3.16(d,J=20.9Hz,4H),2.94–2. 82(m,1H),2.63–2.55(m,2H),2.34(t,J=7.4Hz,2H),2.06–1.90(m,3H),1.83(d ,J=11.9Hz,2H),1.61–1.48(m,4H),1.41(q,J=12.3Hz,2H),1.36–1.12(m,12H).
[0332] Example 42: N-(3-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)amino)butanamide (Compound YJZ9062)
[0333] The synthesis method is similar to that shown in Example 23.
[0334] 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),10.13(s,1H),9.04(s,1H),7.72(dd,J=11.5,7.9Hz,2H),7.66–7.55(m,2H),7.48(s,1H), 7.43–7.35(m,2H),7.30–7.21(m,3H),7.21–7.12(m,5H),7.03(d,J=7.0Hz,1H),6.87(d,J=8.1Hz,1H),6.69(t,J=6.2Hz,1H),5. 79(t,J=6.1Hz,1H),5.05(dd,J=12.8,5.4Hz,1H),4.27(t,J=11.8Hz,1H),4.16(d,J=6.0Hz,2H),3.58(s,1H),2.94–2.81(m,1H) ,2.64–2.53(m,2H),2.45(t,J=7.2Hz,2H),2.07–1.86(m,5H),1.80(d,J=12.1Hz,2H),1.42(q,J=12.2Hz,2H),1.28–1.11(m,4H).
[0335] Example 43: N-(3-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)-8-((2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoindole-4-yl)amino)octanamide (Compound YJZ9059)
[0336] The synthesis method is similar to that shown in Example 23.
[0337] 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),10.03(s,1H),9.04(s,1H),7.74(d,J=8.0Hz,1H),7.69(d,J=8.4Hz,1H),7.65–7.52( m,2H),7.49(s,1H),7.43–7.34(m,2H),7.30–7.20(m,4H),7.20–7.14(m,4H),7.07(d,J=8.6Hz,1H),7.01(d,J=7.1Hz,1H), 6.86(d,J=7.5Hz,1H),6.52(t,J=5.9Hz,1H),5.79(t,J=5.9Hz,1H),5.04(dd,J=13.0,5.4Hz,1H ),4.28(t,J=12.1Hz,1H),4.16(d,J=5.9Hz,2H),3.58(s,1H),3.29(p,J=6.7Hz,2H)2.94–2.80( m,1H),2.63–2.54(m,2H),2.32(t,J=7.3Hz,2H),2.06–1.91(m,3H),1.79(d,J=12.0Hz,2H),1.6 6–1.51(s,4H),1.43(q,J=12.3Hz,2H),1.37–1.31(m,4H),1.28–1.22(m,2H),1.21–1.10(m,2H).
[0338] Example 44: 3-Benzyl-1-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)azetidin-3-ylmethyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1102)
[0339] Step 1: Preparation of tert-butyl 3-(4-(4-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazin-1-yl)methyl)azetidin-1-carboxylate (Compound 11)
[0340] KHCO₃ (345 mg, 2.5 mmol) was added to a mixture of compound 8 (620 mg, 1.2 mmol) and tert-butyl 3-(bromomethyl)azetidine-1-carboxylate 10 (630 mg, 2.5 mmol) in DMF (40 mL). After stirring at 80°C for 5 hours, the reaction mixture was filtered. The filtrate was concentrated by rotary evaporation under reduced pressure and purified by column chromatography to afford 560 mg of a white solid (65% yield). 1H NMR (400MHz, DMSO-d6) δ9.05(s,1H),7.74(d,J=8.0Hz,1H),7.63(t,J=7.8Hz,1H),7.40(d,J=8.7Hz,1H),7.27(t,J=7 .5Hz,2H),7.23(d,J=8.0Hz,1H),7.21–7.12(m,4H),7.01(q,J=9.2Hz,4H),5.57(t,J=6.1Hz,1H),4.26(t,J=12.1Hz,1 H),4.16(d,J=6.0Hz,2H),3.92(s,2H),3.67–3.44(m,4H),3.31(s,2H),3.17(d,J=6.2Hz,4H),2.89(s,1H),2.73(s,1 H),2.57(d,J=7.2Hz,2H),1.96(d,J=11.3Hz,2H),1.79(d,J=11.9Hz,2H),1.47–1.31(m,11H),1.13(q,J=12.6Hz,2H).
[0341] Step 2: Preparation of 1-(4-(4-(azetidin-3-ylmethyl)piperazin-1-yl)phenyl)-3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound 12)
[0342] Tert-butyl 3-(4-(4-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperazin-1-yl)methyl)azetidinium-1-carboxylate 11 (100 mg, 0.14 mmol) was dissolved in DCM (4 mL), TFA (2 mL) was added, and the mixture was stirred and refluxed at 50 ° C. overnight. The reaction mixture was then concentrated under reduced pressure, and the resulting white object (60 mg) was purified by column chromatography (yield 70%).
[0343] Step 3: 3-Benzyl-1-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)azetidin-3-ylmethyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1102)
[0344] 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione 13 (42.9 mg, 0.16 mmol) was dissolved in 6 mL of DMSO, and DIPEA (25.1 mg, 0.19 mmol) and compound 12 (84.5 mg, 0.13 mmol) were added at room temperature. The resulting mixture was stirred at 120°C for 8 hours. After the reaction, the solvent was removed under vacuum, and the compound was purified by column chromatography to obtain 71 mg of the compound as a yellow solid (63% yield). 1 H NMR (400MHz, DMSO-d6) δ11.07(s,1H),9.05(s,1H),7.74(d,J=7.9Hz,1H),7.69–7.59(m,2H),7.40(d,J=8.5Hz,1H),7.32–7.25(m,2H),7.23(d,J=8 .0Hz,1H),7.18(t,J=7.5Hz,4H),7.09–6.95(m,4H),6.79(d,J=2.1Hz,1H) ,6.66(dd,J=8.4,2.1Hz,1H),5.58(t,J=6.1Hz,1H),5.06(dd,J=12.9,5.4 Hz,1H),4.30(t,J=12.4Hz,2H),4.22–4.09(m,4H),3.72(dd,J=8.4,5.4Hz ,2H),3.59(s,1H),3.21(t,J=4.8Hz,4H),3.06(p,J=6.9Hz,1H),2.95–2.8 1(m,1H),2.67(d,J=7.2Hz,2H),2.63–2.53(m,6H),2.08–1.89(m,3H),1.7 9(d,J=11.7Hz,2H), 1.41(q,J=12.3,11.6Hz,2H), 1.13(q,J=12.4Hz,2H). 13C NMR(151MHz,DMSO-d6)δ173.33,170.61,167.99,167.68,162.49,157.35,155.66,150.60,14 1.76,134.46,134.28,132.02(2C),128.68,128.52(3C),128.31,127.16(4C),126.74,125.30 ,122.20,119.95,117.11,115.90(2C),114.55,104.80,62.22,56.21(2C),53.52,53.30(2C) ,49.17(2C),48.06(2C),43.93,40.43,31.75,31.44,30.87(2C),27.47,22.68.HRMS(ESI)for C 49 H 52 N 10 O5[M+H] + ,calcd:861.41949,found:861.4163.HPLC analysis:MeOH-H2O(80:20),11.34min,98.3%purity.
[0345] Example 45: Preparation of 3-benzyl-1-(4-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)piperidin-4-yl)-piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1105)
[0346] The synthesis method is similar to that shown in Example 44.
[0347] 1H NMR(400MHz,DMSO-d6)δ11.08(s,1H),9.05(s,1H),7.74(d,J=8.0Hz,1H),7.67(d,J=8.5Hz,1H),7.63(t,J=7.5Hz,2H),7.40(d,J=8.5Hz,1H),7.34(d,J=2.2Hz,1H),7.30–7.24(m,3H),7.23(d,J=8.1Hz,1H),7.20–7.12(m,4H),7.01(q,J=8.8Hz,4H),5.57(t,J=6.0Hz,1H),5.07(dd,J=12.9,5.4Hz,1H),4.26(t,J=12.1Hz,1H),4.16(d,J=6.0Hz,2H),4.09(d,J=10.1Hz,2H),3.65–3.53(m,1H),3.26–3.12(m,4H),3.00(t,J=12.3Hz,2H),2.94–2.82(m,1H),2.65(t,J=4.9Hz,4H),2.62–2.59(m,1H),2.59–2.53(m,2H),2.07–1.86(m,5H),1.78(d,J=11.6Hz,2H),1.50(q,J=11.1Hz,2H),1.41(q,J=12.5Hz,4H),1.13(q,J=12.5,11.9Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.37,170.61,168.11,167.48,162.50,157.39,155.22,150.62,141.70,134.48,131.99(2C),128.56,128.52(3C),128.32,127.14(4C),126.75,125.53,125.24,122.23,119.94,118.17,118.01,115.79(2C),108.24,60.99,53.51,49.20(3C),48.38(2C),47.06(2C),43.91,40.73,40.36,31.75,31.42,30.85(2C),27.64(2C),22.65.HRMS(ESI)for C 50 H 54 N 10 O5[M+H] +,calcd:875.43514,found:875.4322.HPLC analysis:MeOH-H2O(80:20),11.36min,99.2%purity.
[0348] Example 46: 3-Benzyl-1-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)azetidin-3-yl(piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1103)
[0349] The synthesis method is similar to that shown in Example 44.
[0350] 1 H NMR(400MHz,DMSO-d6)δ11.08(s,1H),9.05(s,1H),7.74(d,J=8.5Hz,1H),7 .67(d,J=8.3Hz,1H),7.63(t,J=7.7Hz,1H),7.40(d,J=8.5Hz,1H),7.31–7.2 5(m,2H),7.23(d,J=7.9Hz,1H),7.21–7.14(m,4H),7.08–6.98(m,4H),6.82( d,J=2.1Hz,1H),6.68(dd,J=8.4,2.1Hz,1H),5.58(t,J=6.3Hz,1H),5.06(dd ,J=12.9,5.4Hz,1H),4.34–4.23(m,1H),4.15(t,J=7.6Hz,4H),3.94(dd,J=8 .8,4.9Hz,2H),3.66–3.51(m,1H),3.45–3.37(m,1H),3.26(t,J=5.7Hz,4H), 2.94–2.80(m,1H),2.64–2.53(m,6H),2.06–1.99(m,1H),1.96(d,J=14.5Hz, 2H), 1.79 (d, J = 11.7Hz, 2H), 1.41 (q, J = 12.4Hz, 2H), 1.13 (q, J = 12.8Hz, 2H). 13C NMR(151MHz,DMSO-d6)δ173.33,170.61,167.97,167.67,162.49,157.35,155 .42,150.54,141.76,134.47,134.29,132.04(2C),128.76,128.52(3C),128.3 1,127.16(4C),126.73,125.35,122.20,119.95,117.33,115.94(2C),114.72 ,104.97,55.50(2C),54.62,53.51,49.59(2C),49.18(2C),47.83(2C),43.92, 40.43,31.74,31.43,30.86(2C),22.67.HRMS(ESI)for C 48 H 50 N 10 O5[M+H] + ,calcd:847.40384,found:847.4000.HPLC analysis:MeOH-H2O(75:25),13.02min,97.9%purity.
[0351] Example 47: 3-Benzyl-1-(4-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)pyrrolidin-3-yl(piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound YJZ1096)
[0352] The synthesis method is similar to that shown in Example 44.
[0353] 1H NMR(400MHz,DMSO-d6)δ11.07(s,1H),9.05(s,1H),7.74(d,J=8.0Hz,1H),7.68–7.59(m,2H),7.40(d,J=8.4Hz,1H),7.28(t,J=7.5Hz,2H),7.23(d,J=8.1Hz,1H),7.18(t,J=7.3Hz,4H),7.04(s,4H),6.99(s,1H),6.87(d,J=9.0Hz,1H),5.58(d,J=7.0Hz,1H),5.06(dd,J=12.7,5.4Hz,1H),4.30(t,J=12.4Hz,1H),4.16(d,J=5.9Hz,2H),3.75(t,J=8.4Hz,1H),3.66–3.53(m,2H),3.42(q,J=8.8Hz,2H),3.31–3.27(m,1H),3.24(t,J=6.2Hz,4H),3.02(p,J=7.6Hz,1H),2.95–2.82(m,1H),2.67(s,4H),2.63–2.53(m,2H),2.34–2.26(m,1H),2.05–1.88(m,4H),1.79(d,J=11.7Hz,2H),1.41(q,J=12.4Hz,2H),1.13(q,J=12.8Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.35,170.65,168.20,167.74,162.49,157.36,152.27,150.57,141.76,134.46,132.03(2C),128.74,128.52(4C),128.31,127.15(4C),126.74,125.41,122.21,119.95,116.22,115.92(2C),115.71,106.05,63.97,53.52,52.42,51.76(2C),49.15(2C),48.05(2C),47.49,43.93,40.43,31.76,31.45,30.87(2C),29.28,22.71.HRMS(ESI)for C 49 H 52 N 10 O5[M+H] + ,calcd:861.41949,found:861.4168.HPLC analysis:MeOH-H2O(75:25),15.48min,98.2%purity.
[0354] Example 48: 3-Benzyl-1-(4-(4-((1-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1097)
[0355] The synthesis method is similar to that shown in Example 44.
[0356] 1 H NMR (600MHz, DMSO-d6) δ11.09(s,1H),9.05(s,1H),7.75(d,J=7.9Hz,1H),7. 66(d,J=8.5Hz,1H),7.63(t,J=7.6Hz,1H),7.41(d,J=8.6Hz,1H),7.32(s,1H) ,7.30–7.26(m,2H),7.24(d,J=8.8Hz,2H),7.21–7.13(m,4H),7.02(q,J=8.7 Hz,4H),5.58(t,J=6.1Hz,1H),5.07(dd,J=12.8,5.5Hz,1H),4.29(t,J=11.7H z,1H),4.16(d,J=6.0Hz,2H),4.06(d,J=12.8Hz,2H),3.65–3.54(m,1H),3.2 6–3.15(s,4H),2.99(t,J=12.3Hz,2H),2.93–2.83(m,1H),2.64–2.54(m,2H), 2.52(m,4H),2.21(d,J=5.2Hz,2H),2.05–1.99(m,1H),1.99–1.93(m,2H),1.9 2–1.85(m,1H),1.85–1.75(m,4H),1.41(q,J=12.4Hz,2H),1.20–1.09(m,4H). 13C NMR(151MHz,DMSO-d6)δ173.30,170.60,168.12,167.45,162.48,157.32,155.48,150.62,141.81,134.52,134.42,132.02(2C), 128.67,128.51(3C),128.31,127.16(4C),126.71,125.49,125.28,122.17,119.96,118.06,117.80,115.83(2C),108.21,64.18,53. 68(2C),53.52,49.20(2C),48.15,47.74(2C),43.94,40.51,32.94,31.76,31.45,30.88(2C),30.11(2C),29.45,22.67.HRMS(ESI)for C 51 H 56 N 10 O5[M+H] + ,calcd:889.45079,found:889.4473.HPLC analysis:MeOH-H2O(80:20),15.05min,96.9%purity.
[0357] Example 49: 3-Benzyl-1-(4-(4-(1-(2-(2-(2,6-dioxapiperidin-3-yl)-6-fluoro-1,3-dioxoisoindole-5-yl)piperidin-4-yl)-piperazin-1-yl)phenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1201)
[0358] The synthesis method is similar to that shown in Example 44.
[0359] 1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),9.05(s,1H),7.77–7.68(m,2H),7.63(t,J=7.9Hz,1H),7.47(d,J=7.3Hz,1H),7.40(d,J=8.5Hz,1H),7.31–7.24(m,2H),7.23(d,J=7.0Hz,1H),7.21–7.13(m,4H),7.07–6.95(m,4H),5.57(t,J=6.8Hz,1H),5.11(dd,J=13.1,5.3Hz,1H),4.28(t,J=11.4Hz,1H),4.16(d,J=5.8Hz,2H),3.68(d,J=11.7Hz,2H),3.58(s,1H),3.21(s,4H),2.99–2.82(m,3H),2.68(s,4H),2.64–2.54(m,3H),2.08–1.89(m,5H),1.78(d,J=9.6Hz,2H),1.61(q,J=12.2Hz,3H),1.41(q,J=14.5,13.7Hz,2H),1.13(q,J=13.1Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.25,170.40,167.17,166.69,162.47,158.57(d,J=253.3Hz,1C),157.32,150.63,146.01(d,J=8.8Hz,1C),141.82,134.43,132.02(2C),129.26(d,J=2.2Hz,1C),128.65,128.50(3C),128.30,127.16(4C),126.71,123.51(d,J=9.6Hz,1C),122.17,119.96,115.79(2C),114.23(d,J=4.8Hz,1C),112.49(d,J=25.3Hz,1C),60.86,53.52,52.46,49.84,49.81,49.51,49.25(2C),48.49(2C),43.94,40.51,31.78,31.42,30.87(2C),28.35(2C),22.55.HRMS(ESI)for C 50 H 53 N 10 O5F[M+H] +,calcd:893.42572,found:893.4229.HPLC analysis:MeOH-H2O(80:20),11.79min,95.8%purity.
[0360] Example 50: 1-(4-(4-(1-(1-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperidin-4-yl)-piperazin-1-yl)phenyl)-3-(2-fluorobenzyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1203)
[0361] The synthesis method is similar to that shown in Example 44.
[0362] 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),9.05(s,1H),7.74(d,J=8.0Hz,1H),7.67( d,J=8.6Hz,1H),7.63(t,J=7.7Hz,1H),7.40(d,J=8.6Hz,1H),7.34(s,1H),7.29 –7.14(m,6H),7.14–7.08(m,1H),7.03(q,J=8.6Hz,4H),5.59(s,1H),5.07(dd,J=13.4, 5.5Hz,1H),4.31–4.17(m,3H),4.10(d,J=12.7Hz,2H),3.58(s,1H),3.20(s,4H),3.00( t,J=12.3Hz,2H),2.95–2.82(m,1H),2.66(s,4H),2.63–2.53(m,3H),2.07–1.86(m,5H) ,1.79(d,J=11.9Hz,2H),1.50(q,J=11.5Hz,2H),1.44–1.33(m,2H),1.20–1.09(m,2H). 13C NMR (151MHz, DMSO-d6) δ173.30, 170.59, 168.09, 167.44, 162.47, 161.01 (d, J = 243.4Hz, 1C), 157.23, 155.23, 150.66, 134. 51,134.43,131.98(2C),129.03(d,J=4.7Hz,2C),128.58,128.55,128.53,128.44(d,J=14.2Hz,1C),128.30,125.49,125.2 9,124.61(d,J=3.3Hz,1C),122.17,119.96,118.18,118.10,115.81(2C),115.12(d,J=21.1Hz,1C),108.29,61.02,53.57, 49.25(2C),49.21,49.10,48.46(2C),47.09(2C),40.51,37.73,31.76,31.45,30.84(2C),27.67(2C),22.66.HRMS(ESI)for C 50 H 53 N 10 O5F[M+H] + ,calcd:893.42572,found:893.4224.HPLC analysis:MeOH-H2O(80:20),9.19min,96.2%purity.
[0363] Example 51: 3-Benzyl-1-(6-(4-(1-(1-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperidin-4-yl)pyrazin-1-yl)pyridin-3-yl]-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1205)
[0364] The synthesis method is similar to that shown in Example 44.
[0365] 1H NMR(400MHz,DMSO-d6)δ11.08(s,1H),9.05(s,1H),7.91(s,1H),7.74(d,J=8.0Hz,1H),7.70–7.58(m,2H),7.40(d,J=8.4Hz,1H),7.34(s,2H),7.31–7.21(m,4H),7.21–7.13(m,4H),6.88(d,J=9.0Hz,1H),6.05(t,J=6.6Hz,1H),5.07(dd,J=12.8,5.3Hz,1H),4.26(t,J=12.8Hz,1H),4.12(dd,J=18.7,9.2Hz,4H),3.60(s,1H),3.52(s,4H),3.00(t,J=12.4Hz,2H),2.94–2.81(m,1H),2.70–2.53(m,7H),2.07–1.93(m,3H),1.90(d,J=12.2Hz,2H),1.78(d,J=11.7Hz,2H),1.57–1.33(m,4H),1.09(q,J=12.9Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ173.30,170.59,168.09,167.44,162.47,158.32,157.45,155.22,149.85,141.82,140.60,134.51,134.43,128.48(3C),128.31,127.18(4C),126.68,125.49,124.43,122.17,119.97,118.17,118.09,108.28,107.40,61.12,55.39,53.49,49.21(2C),49.10(2C),47.10(2C),45.29,43.96,31.70,31.45,30.85(2C),27.66(2C),22.66.HRMS(ESI)for C 49 H 53 N 11 O5[M+H] + ,calcd:876.43039,found:876.4276.HPLC analysis:MeOH-H2O(80:20),6.94min,97.8%purity.
[0366] Example 52: 3-Benzyl-1-(6-(4-(1-(1-(2-(2-(2,6-dioxapiperidin-3-yl)-6-fluoro-1,3-dioxoisoindole-5-yl)piperidin-4-yl)pyrrolazin-1-yl)pyridin-3-yl]-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1206)
[0367] The synthesis method is similar to that shown in Example 44.
[0368] 1 H NMR (400MHz, DMSO-d6) δ11.11(s,1H),9.05(s,1H),7.92(s,1H),7.73(t,J=9.7Hz,2H),7.63(t,J=8.0Hz,1H),7.46(d,J=7.4Hz,1H),7.41(d,J= 8.5Hz,1H),7.35(d,J=9.1Hz,1H),7.31–7.25(m,2H),7.21(d,J=7.5Hz, 1H),7.21–7.13(m,3H),6.90(d,J=9.0Hz,1H),6.05(t,J=5.4Hz,1H),5.1 1(dd,J=13.0,5.3Hz,1H),4.28(t,J=12.3Hz,1H),4.15(d,J=6.0Hz,2H),3.68(d,J=11.9Hz,2H),3.63–3.48(m,5H),2.99–2.82(m,3H),2.64(s, 4H),2.59–2.52(m,3H),2.08–1.87(m,5H),1.79(d,J=11.7Hz,2H),1.61 (d, J=12.0Hz, 2H), 1.41 (q, J=13.6, 13.0Hz, 2H), 1.10 (d, J=12.8Hz, 3H). 13C NMR (151MHz, DMSO-d6) δ173.25, 170.40, 167.17, 166.69, 162.47, 158.33, 157.45, 156.89 (d, J = 253.4Hz, 1C), 149.86, 146. 00(d,J=8.49Hz,1C),141.83,140.60,134.42,129.26(d,J=2.2Hz,1C),128.48(3C),128.30,127.19(4C),126.69,125.28,1 24.42,123.52(d,J=9.9Hz,1C),122.17,119.97,114.24(d,J=4.5Hz,1C),112.48(d,J=25.5Hz,1C),107.40,60.96,55.39, 53.50,49.84(2C),49.52(2C),49.11(2C),45.30,43.97,40.51,31.72,31.42,30.85(2C),28.32(2C),22.55.HRMS(ESI)for C 49 H 52 N 11 O5F[M+H] + ,calcd:894.42097,found:894.4176.HPLC analysis:MeOH-H2O(80:20),8.79min,98.9%purity.
[0369] Example 53: 3-Benzyl-1-(4-(4-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperazin-1-yl)piperidin-1-ylphenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1202)
[0370] Step 1: Preparation of tert-butyl ((1r,4r)-4-((4-bromophenyl)amino)cyclohexyl)carbamate (Compound 16)
[0371] Compound 14 (5.0 g, 17.7 mmol), compound 15 (3.2 g, 14.7 mmol), Pd2(dba)3 (1.37 mg, 1.5 mmol), Xantphos (1.7 g, 2.94 mmol), and tert-ButONa (2.8 g, 29.4 mmol) were dissolved in 150 mL of toluene. The atmosphere was replaced with argon three times, and the reaction mixture was heated to 100°C overnight. After completion of the reaction, the reaction mixture was filtered through celite and concentrated under reduced pressure. Purification by column chromatography afforded 3.9 g of a yellow solid (72% yield). 1 H NMR (400MHz, DMSO-d6) δ7.15(d,J=6.8Hz,2H),6.76(d,J=7.9Hz,1H),6.50(d,J=8.9Hz,2H),5.60(d,J=8.0Hz,1H),3.27–3.13(m,1H), 3.12–2.99(m,1H),1.94(d,J=12.7Hz,2H),1.79(d,J=12.4Hz,2H),1.38(s,9H),1.26(q,J=12.2,11.3Hz,2H),1.14(q,J=12.2Hz,2H).
[0372] Step 2: Preparation of tert-butyl ((1r,4r)-4-(3-benzyl-1-(4-bromophenyl)ureido)cyclohexyl)carbamate (Compound 17)
[0373] Compound 16 (3.9 g, 10.6 mmol) was dissolved in 4 mL of DMF, and benzyl isocyanate 6 (4.2 g, 31.7 mmol) and DIPEA (1.59 g, 12.3 mmol) were added. The mixture was reacted at 95°C for 5 h. The solvent was evaporated and column chromatography was performed to obtain 3.7 g of a yellow solid (yield 69%). 1 H NMR (400MHz, DMSO-d6) δ7.63(d,J=8.4Hz,2H),7.30–7.22(m,2H),7.20–7.14(m,3H),7.11(d,J=7.5Hz,2H),6.66(d,J=8.0Hz,1H),5.98(t,J= 6.2Hz,1H),4.22–4.07(m,3H),3.02–2.87(m,1H),1.73(d,J=10.8Hz,4H),1.35(s,9H),1.24(q,J=12.5Hz,2H),1.01(q,J=12.5,12.0Hz,2H).
[0374] Step 3: Preparation of 1-((1r, 4r)-4-aminocyclohexyl)-3-benzyl-1-(4-bromophenyl)urea (Compound 18)
[0375] Compound 17 (3.7 g, 7.3 mmol) was dissolved in 5 mL of DCM, and 2.5 mL of trifluoroacetic acid (TFA) was added. The mixture was heated to 55°C and refluxed for 6 h. The solvent was evaporated under reduced pressure and column chromatography was performed to obtain 2.5 g of the target compound as a yellow solid (yield 70%). 1 H NMR (400MHz, DMSO-d6) δ7.62(d,J=8.0Hz,2H),7.30–7.22(m,2H),7.21–7.14(m,3H),7.11(d,J=8.0Hz,2H),5.95(t,J=6.1Hz,1H),4.20(t, J=11.9Hz,1H),4.14(d,J=6.1Hz,2H),2.26(t,J=7.8Hz,1H),1.80–1.60(m,4H),1.10(q,J=11.9,11.2Hz,2H),0.98(q,J=12.5,12.1Hz,2H).
[0376] Step 4: Preparation of 3-benzyl-1-(4-bromophenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (Compound 19)
[0377] Compound 18 (2.5 g, 5.1 mmol) was dissolved in 15 mL of DMF, and 2-chloroquinazoline 4 (1.0 g, 6.1 mol) and Cs2CO3 (2.0 g, 6.1 mol) were added. The mixture was stirred at room temperature for 15 minutes and then heated to 60°C for 40 minutes. After the reaction, the solvent was evaporated under reduced pressure and purified by column chromatography to obtain 1.9 g (70% yield). 1 H NMR (400MHz, DMSO-d6) δ9.05 (s, 1H), 7.74 (d, J = 8.0Hz, 1H), 7.69–7.59 (m, 3H), 7.40 (d ,J=8.5Hz,1H),7.31–7.25(m,2H),7.23(d,J=7.8Hz,1H),7.21–7.12(m,6H),6.02(t,J =6.2Hz,1H),4.29(t,J=12.5Hz,1H),4.16(d,J=5.9Hz,2H),3.68–3.53m,1H),1.98(d, J=13.6Hz,2H),1.81(d,J=12.1Hz,2H),1.42(q,J=12.4Hz,2H),1.13(q,J=12.5Hz,2H).
[0378] Step 5: Preparation of tert-butyl 4-(1-(4-(3-benzyl-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)ureido)phenyl)piperidin-4-yl)piperazine-1-carboxylate (Compound 21)
[0379] Compound 19 (1.9 g, 3.6 mmol), compound 20 (1.25 g, 4.6 mmol), Pd2(dba)3 (327 mg, 0.36 mmol), Xantphos (414 mg, 0.72 mmol), and tert-ButONa (688 mg, 7.2 mmol) were dissolved in 80 mL of toluene. The atmosphere was replaced with argon three times, and the reaction mixture was heated to 100°C overnight. After completion of the reaction, the reaction mixture was filtered through celite and concentrated under reduced pressure. Purification by column chromatography afforded 1785 mg of a light yellow solid (yield 69%). 1 H NMR(400MHz, DMSO-d6)δ9.05(s,1H),7.74(d,J=8.2Hz,1H),7.66–7.60(m,1H),7.40(d,J=9.1Hz,1H),7.30–7.24(m,2H),7.24–7.13(m,5H),7. 04–6.95(m,4H),5.53(t,J=7.4Hz,1H),4.29(t,J=12.6Hz,1H),4.16(d, J=6.0Hz,2H),3.79(d,J=12.1Hz,2H),3.65–3.51(m,1H),3.30(s,4H),2 .71(t,J=12.1Hz,2H),2.46(s,4H),2.35(t,J=11.5Hz,1H),2.01–1.91(m,2H),(d,J=15.7Hz,2H),1.87(d,J=11.8Hz,2H),1.78(d,J=12.0Hz,2H),1.48(q,J=12.0Hz,2H),1.44–1.32(m,11H),1.13(q,J=12.5Hz,2H).The above reaction product was dissolved in 5mL of dichloromethane, 2.5mL of trifluoroacetic acid was added, and the mixture was refluxed at 55℃ for 4h. After removing the Boc protecting group, 1.1g was obtained for the next step.
[0380] Step 6: Preparation of 3-benzyl-1-(4-(4-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperazin-1-yl)piperidin-1-ylphenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1202)
[0381] Compound 21 was treated by a similar method to that in step 3 of Example 44 to obtain YJZ1102. 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),9.05(s,1H),7.74(d,J=8.0Hz,1H),7.68(d,J=8.4Hz,1H),7.63(t,J=7.9Hz,1H),7.40(d,J=8.5Hz,1H), 7.34(s,1H),7.31–7.21(m,4H),7.21–7.13(m,4H),7.01(s,4H),5.55(t,J=6.5Hz,1H),5.08(dd,J=13.0,5.4Hz,1H),4.28(t,J=12.3Hz,1H),4 .16(d,J=6.0Hz,2H),3.81(d,J=11.7Hz,2H),3.59(s,1H),3.44(s,4H) ,2.95–2.83(m,1H),2.74(t,J=11.8Hz,2H),2.66(s,4H),2.63–2.53(m, 2H), 2.40(t,J=11.0Hz,1H),2.06–1.87(m,5H),1.79(d,J=11.9Hz,2H),1.53(q,J=11.9Hz,2H),1.41(q,J=12.5Hz,2H),1.13(q,J=12.6Hz,2H). 13 C NMR (151MHz, DMSO-d6) δ173.29,170.56,168.04,167.47,162.47,157.33,155.73,150.64,141. 80,134.42,134.32,131.99(2C),128.51(3C),128.38,128.30,127.16(4C),126.71,125.36,12 2.17,119.96,118.76,118.21,116.24(2C),108.28,61.03,53.53,49.24,49.13,48.91(2C),47 .94(2C),47.71(2C),43.94,40.51,31.77,31.45,30.88(2C),28.38(2C),22.65.HRMS(ESI)for C 50 H 54 N 10 O5[M+H] +,calcd:875.43514,found:875.4315.HPLC analysis:MeOH-H2O(80:20),9.43min,95.2%purity.
[0382] Example 54: 3-Benzyl-1-(4-(4-(1-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperidin-4-yl)-piperazin-1-yl)-3-fluorophenyl)-1-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)urea (YJZ1204)
[0383] The synthesis method is similar to that shown in Example 53.
[0384] 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),9.05(s,1H),7.74(d,J=8.0Hz,1H),7.69–7.59(m,2H),7.40(d,J=8.5Hz,1H),7.34(s,1H),7.31–7.2 1(m,4H),7.21–7.14(m,4H),7.06(t,J=9.2Hz,1H),7.02–6.91(m,2H),5.92(t,J=6.4Hz,1H),5.07(dd,J=13.2,5.4Hz,1H),4.24(t,J=13.3 Hz,1H),4.10(d,J=12.7Hz,2H),3.67–3.54(m,1H),3.08(s,4H),3.00(t,J=12.3Hz,2H),2.94–2.82(m,1H),2.67(s,4H),2.63–2.53(m,3H) ,2.07–1.93(m,3H),1.90(d,J=12.4Hz,2H),1.81(d,J=11.8Hz,2H),1.50(q,J=11.8Hz,2H),1.40(q,J=12.2Hz,2H),1.14(q,J=11.9Hz,2H). 13C NMR(151MHz,DMSO-d6)δ173.30,170.59,168.09,167.44,162.48,157.02,155.23,153.97(d,J=246.4Hz,1C),141.77 ,139.82(d,J=8.1Hz,1C),134.51,134.44,132.01(d,J=9.2Hz,1C),128.49(3C),128.32,128.04,127.17(4C),126.7 0,125.49,122.18,119.97,119.43,119.30(d,J=14.5Hz,1C),118.09(d,J=14.1Hz,1C),108.29,61.06,53.80,50.74 ,49.27(2C),49.21(2C),49.06,47.10(2C),43.94,40.51,31.76,31.45,30.77(2C),27.64(2C),22.66.HRMS(ESI)for C 50 H 53 N 10 O5F[M+H] + ,calcd:893.42572,found:893.4225.HPLC analysis:MeOH-H2O(80:20),10.01min,95.8%purity.
[0385] Example 55: Testing of representative compounds for CDK12 / 13 degradation activity in MDA-MB-231 cells
[0386] Experimental method: The cell line MDA-MB-231 was purchased from the American Type Culture Collection (ATCC). Conventional Western Blot was used for detection as follows: MDA-MB-231 cells were plated at 2×10 5Cells were seeded at a density of 1 mL / mL in 12-well plates and allowed to adhere overnight in an incubator. Compounds were then added at a specific concentration for 15 hours, followed by lysis with lysis buffer and protein samples collected. An appropriate amount of sample was subjected to SDS-PAGE electrophoresis. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes using a wet electrotransfer system. The membranes were cut into the desired bands and blocked in blocking buffer (5% skim milk powder diluted in TBS containing 0.1% Tween 20) for 1.5 hours at room temperature. Primary antibody solutions were prepared by diluting the primary antibody corresponding to the target protein in TBS containing 0.1% Tween 20 according to the dilution requirements of the respective antibodies, such as 1:1000 (CST), 1:3000 (Proteintech, Bethyl), or 1:200 (Santacruz). The blocked membranes were then incubated in the corresponding primary antibody solutions at 4°C for 12-14 hours. Then wash the membrane three times with TBS containing 0.1% Tween 20, each time for 5 minutes. After washing, place the membrane in the secondary antibody solution (horseradish peroxidase-labeled goat anti-rabbit IgG, diluted 1:2000 in TBS containing 0.1% Tween 20) at room temperature for 2 hours. After washing the membrane three times as above, use StarSignal plus reagent and Omni-ECL reagent Hair color was taken with Amersham Imager 800 system.
[0387] The results in Figure 1 demonstrate that some compounds, such as ZLC4-77, ZLC4-91, ZLC5-6, ZLC5-11, ZLC7-36, ZLC5-106, ZLC6-1, ZLC6-37, ZLC6-42, and ZLC6-103, can effectively degrade CDK12 and CDK13 protein levels in cells. The results in Figure 2 demonstrate that compounds ZLC4-91 and ZLC5-11 can degrade CDK12 and CDK13 protein in a time-dependent manner in MDA-MB-231 cells, with the proteins being almost completely degraded after 15 hours of treatment at a 1 μM concentration. Furthermore, the compounds exhibit a time-dependent degradation effect on Cyclin K, a partner protein of CDK12 and CDK13, with Cyclin K protein in the cells being almost completely degraded after 15 hours.
[0388] We further measured the degradation of CDK12 and CDK13 proteins in MDA-MB-231 cells at different concentrations using representative compounds. The results showed that these representative compounds could dose-dependently degrade CDK12 and CDK13 proteins in MDA-MB-231 cells, with effective degradation at a concentration of 1 μM (Figure 2).
[0389] Figure 1, (A) Western blotting results of CDK12 and CDK13 protein degradation in MDA-MB-231 cells treated with some compounds at a concentration of 0.1 μM for 15 hours; (B) Western blotting results of CDK12 and CDK13 protein degradation in MDA-MB-231 cells treated with some compounds at a concentration of 0.3 μM for 15 hours; (C) Using the control group DMSO as a reference standard, the CDK12 / 13 levels were quantified by the grayscale values of the bands in the WB result image (Figure A); (D) Using the control group DMSO as a reference standard, the CDK12 / 13 levels were quantified by the grayscale values of the bands in the WB result image (Figure B).
[0390] Figure 2, (A) Representative compounds time-dependently degrade CDK12 and CDK13 proteins in MDA-MB-231 cells; (B) Western blotting analysis of CDK12 / 13 protein levels in MDA-MB-231 cells after treatment with different concentrations of representative compounds for 15 hours.
[0391] Example 56: Study on the proliferation inhibitory activity of the compound on triple-negative breast cancer cells MDA-MB-231
[0392] The cell proliferation inhibitory activity of the compound was determined using Cell Counting Kit-8 Cell Viability Assay (Selleck.cn). Cells were seeded in 384-well plates ( PS 3701) and incubated in a 37°C incubator containing 5% CO2. After overnight incubation, a high concentration stock solution of each test compound was prepared; 650 Liquid Handler The compound was added to a 384-well plate according to a certain concentration gradient. After the administration, the cell plate was placed in an incubator at 37°C with 5% CO2 for 5 days. (Thermo Scientific TM ) Add 5 μL of cck-8 reagent to each well of the 384-well plate and return the plate to the incubator for 1.5-2 hours. After incubation, remove the plate and centrifuge to remove bubbles before use. The absorbance values of each well were obtained at 450 nm and 650 nm, and the data were processed and analyzed using GraphPad Prism software (GraphPad Software Inc).
[0393] The results in Figure 3 show that compounds that can effectively degrade CDK12 and CDK13 protein levels, such as ZLC4-77, ZLC4-91, ZLC5-6, ZLC5-31, and ZLC6-1, can effectively inhibit the growth of triple-negative breast cancer cells MDA-MB-231. The IC values of the MDA-MB-231 cell line are 50 They are 610.4nM, 622.5nM, 497.9nM, 389.0nM and 288.6nM respectively.
[0394] Example 57: In vivo pharmacokinetic study of representative compounds zlc-4-91 and zlc-4-93, cell cycle-dependent protein kinase 12 / 13 (CDK12 / 13) degraders
[0395] Pharmacokinetic and bioavailability study in rats. SD rats were given a single oral (10 mg / kg), intravenous (2.5 mg / kg) and intraperitoneal injection (10 mg / kg) dose. Blood samples were collected at appropriate time points after administration, anticoagulated with heparin, centrifuged at 8000 rpm for 6 minutes, and the supernatant was taken and stored at -20°C for HPLC-MS analysis. The blood samples were precipitated with acetonitrile for protein precipitation at 12000 rpm*10 min, and the supernatant was used for HPLC-MS analysis. The data were fitted with parameters using DAS2.0 to obtain the compartment model and non-compartmental model parameters respectively. The oral bioavailability of the compound was calculated based on the area under the blood concentration-time curve (AUC) data. The results are shown in Table 1. The experimental results show (Table 1) that the representative compounds zlc-4-91 and zlc-4-93 have excellent oral pharmacokinetic properties.
[0396] Table 1. Pharmacokinetic results of compound zlc-4-93
[0397] C max Refers to the maximum blood drug concentration, T 1 / 2 is the half-life, CL refers to the clearance, and F refers to the bioavailability.
[0398] Example 58: Testing of CDK12 / 13 degradation activity of representative compounds in 22RV1 cells
[0399] Experimental Methods: Cell line: 22RV1 cell line was purchased from the American Type Culture Collection (ATCC). Standard Western blotting was performed as follows: 22RV1 cells were seeded in 12-well plates at a predetermined number and allowed to adhere overnight in an incubator. Compounds at a predetermined concentration were then added for 6 hours, and the cells were lysed with lysis buffer for sample collection. Appropriate amounts of sample were then subjected to SDS-PAGE electrophoresis. Following electrophoresis, proteins were transferred to a nitrocellulose membrane using a semi-dry electrotransfer system. The membrane was blocked in blocking buffer (5% nonfat dry milk diluted in TBS containing 0.1% Tween 20) for 2 hours at room temperature. The membrane was then incubated in primary antibody solution (1:1000 diluted in TBS containing 0.1% Tween 20) overnight at 4°C. Wash three times with TBS containing 0.1% Tween 20 for 15 minutes each. The membrane was incubated in a secondary antibody solution (horseradish peroxidase-conjugated goat anti-rabbit IgG, diluted 1:1000 in TBS containing 0.1% Tween 20) at room temperature for 1 hour. The membrane was washed three times as above and developed with ECL plus reagent, and photographed using an Amersham Imager 600 system.
[0400] The results in Figure 4 show that some compounds can effectively degrade the levels of CDK12 and CDK13 proteins in cells, such as compounds YJZ9069, YJZ1102, YJZ1105, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205, and YJZ1206. Among them, compound YJZ9069 can dose-dependently degrade CDK12 and CDK13 proteins in 22RV1 cells. After treating 22RV1 cells at a concentration of 0.5 μM for 15 hours, compound YJZ9069 almost completely degraded CDK12 and CDK13 proteins in cells, and dose-dependently inhibited the phosphorylation of serine 2 at the C-terminus of RNA polymerase II (RNA Pol II) (phoSer2).
[0401] We further measured the degradation of CDK12 and CDK13 proteins in 22RV1 cells by representative compounds YJZ9069, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205, and YJZ1206 at different concentrations (Figure 2). Western blotting results showed that representative compounds YJZ9069, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205, and YJZ1206 could dose-dependently degrade CDK12 and CDK13 protein levels in 22RV1 cells, and almost completely degraded CDK12 and CDK13 proteins in cells at a concentration of 100 nM (Figure 5).
[0402] Figure 4. (A) Western blot analysis of CDK12 and CDK13 protein degradation in 22RV1 cells after treatment with some compounds at 500 nM for 6 hours. (B) Compound YJZ9069 dose-dependently degrades CDK12 and CDK13 proteins in 22RV1 cells and dose-dependently inhibits phosphorylation of RNA polymerase II (RNA Pol II) at the C-terminal serine 2 (phoSer2). (C) Western blot analysis of CDK12 and CDK13 protein degradation in LnCap cells after treatment with some compounds at 500 nM for 6 hours. (D) Protein levels were quantified by grayscale analysis of the bands in the Western blot images (Panels A and C), using the DMSO control as the reference standard.
[0403] Figure 5. Western blot analysis of intracellular CDK12 and CDK13 protein levels in 22RV1 cells after treatment with representative compounds YJZ9069, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205, and YJZ1206 at different concentrations for 6 hours.
[0404] Example 59: Study on the Proliferation Inhibitory Activity of Compounds on Prostate Cancer VCap Cells
[0405] The cell proliferation activity of the compounds was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). Cells were seeded on 96-well plates in their respective culture media and incubated at 37°C in a 5% CO2 incubator. After overnight incubation, serial dilutions of the compounds were prepared and added to the 96-well plates. A volume of CellTiter-Glo reagent equal to the volume of cell culture medium present in each well was added (e.g., 100 microliters of reagent was added to 100 microliters of culture medium for 96-well plate cells). The contents were mixed on an orbital shaker for 2 minutes to induce cell lysis. The 96-well plates were incubated at room temperature for 10 minutes to stabilize the luminescent signal. Luminescence was recorded: The luminescent signal for each well was acquired using an Infinite M1000Pro plate reader (Tecan, Zürich, Switzerland), and the data were analyzed using GraphPad Prism software (GraphPad Software Inc, La Jolla, CA).
[0406] The results in Figure 6 show that compounds that can effectively degrade CDK12 and CDK13 protein levels, such as YJZ9069, YJZ1102, YJZ1105, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205 and YJZ1206, can potently inhibit the growth of prostate cancer Vcap cells. The IC 50 The IC values of compounds that cannot effectively induce CDK12 and CDK13 protein degradation, such as YJZ9055 and YJZ1078, on VCap cell lines are 22.90nM, 16.31nM, 15.11nM, 64.4nM, 17.46nM, 18.78nM, 23.31nM, 3.93nM, and 13.50nM, respectively. 50 The results were 2202nM and >5μM, respectively, indicating that this series of compounds effectively inhibited the growth of Vcap cells due to the degradation of CDK12 and CDK13 proteins.
[0407] Example 60: In vivo pharmacokinetic studies of representative compounds YJZ9069, YJZ1102, YJZ1105, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205 and YJZ1206, which are cell cycle-dependent protein kinases 12 / 13 (CDK12 / 13) degraders
[0408] Pharmacokinetic and bioavailability study in rats. SD rats were administered a single oral dose (10 mg / kg), intravenous dose (2.5 mg / kg), and intraperitoneal injection (10 mg / kg). Blood samples were collected at appropriate time points after administration, anticoagulated with heparin, centrifuged at 8000 rpm for 6 minutes, and the supernatant was taken and stored at -20°C for HPLC-MS analysis. The blood samples were precipitated with acetonitrile for protein precipitation at 12000 rpm*10 min, and the supernatant was used for HPLC-MS analysis. The data were fitted with parameters using DAS2.0 to obtain compartmental model and non-compartmental model parameters, respectively. The oral bioavailability of the compound was calculated based on the area under the blood concentration-time curve (AUC) data. The results are shown in Table 2-6. The experimental results show (Table 2-6) that the representative compounds YJZ1102, YJZ1105, YJZ1201, YJZ1202, YJZ1203, YJZ1204, YJZ1097, YJZ1205 and YJZ1206 have excellent oral pharmacokinetic properties.
[0409] Table 2. Pharmacokinetic results of compounds YJZ9069 and YJZ1102
[0410] Cmax Refers to the maximum blood drug concentration, T 1 / 2 is the half-life, CL refers to the clearance, and F refers to the bioavailability.
[0411] Table 3. Pharmacokinetic results of compounds YJZ1105 and YJZ1202
[0412] C max Refers to the maximum blood drug concentration, T 1 / 2 is the half-life, CL refers to the clearance, and F refers to the bioavailability.
[0413] Table 4. Pharmacokinetic results of compounds YJZ1203 and YJZ1204
[0414] C max Refers to the maximum blood drug concentration, T 1 / 2 is the half-life, CL refers to the clearance, and F refers to the bioavailability.
[0415] Table 5. Pharmacokinetic results of compounds YJZ1205 and YJZ1201
[0416] C max Refers to the maximum blood drug concentration, T 1 / 2 is the half-life, CL refers to the clearance, and F refers to the bioavailability.
[0417] Table 6. Pharmacokinetic results of compounds YJZ1206 and YJZ1097
[0418] C max Refers to the maximum blood drug concentration, T 1 / 2 is the half-life, CL refers to the clearance, and F refers to the bioavailability.
[0419] All documents mentioned in this application are cited as references in this application, just as each document is cited as a reference individually. The above-mentioned embodiments only express several implementation methods of the present invention. The description is relatively specific and detailed, but it should not be understood as limiting the scope of the invention patent. The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
Claims
1. A compound having the structure of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, or a prodrug molecule thereof: in, Z is: CH2 or CO; V is selected from the following group: X and Y are each independently selected from the following group: N, CH or CR3; Wherein, R3 is selected from the following group: halogen, cyano, hydroxyl, amino, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, halogenated C1-C3 alkoxy, C3-C8 cycloalkyl, or 3-8 membered heterocyclyl; B is selected from the following group: NH, O, CO, CH2; wherein each U and W are independently selected from the following group: N or CH; each m, p, m', p' are independently: 0, 1, 2 or 3; Ring A is selected from the group consisting of: Wherein, Q and W are each independently selected from: CH, N; R' is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, substituted hydroxyl, amino, substituted amino, C1-C5 alkyl, halogenated C1-C5 alkyl, C1-C5 alkoxy, halogenated C1-C5 alkoxy, C3-C8 cycloalkyl, and when Q and W are independently selected from CH, R' can be a substituent on Q and W; D, E, F, and G are each independently selected from the following group: CH, N, and CR6; wherein R6 is selected from the following group: halogen, trifluoromethyl, hydroxyl, cyano, amino, methyl, methoxy, and trifluoromethoxy; and when any one of D, E, F, and G is CH, the atom can serve as a connection site with the linker, and in this case, D, E, F, or G is C; R1 is selected from the group consisting of H, -NHR7, -OR7, -(C(R9)R8)R7; Where R7 is -R 10 、-CH2R 10 or -(CH2)2R 10 ; R8 and R9 are each independently selected from the following group: hydrogen, halogen, cyano, methyl, halomethyl, methoxy, halomethoxy, ethyl, haloethyl, ethoxy, haloethoxy, hydroxyl, amino, 3-8 membered heterocycle containing 1, 2 or 3 heteroatoms, wherein the heteroatoms are selected from O, S or N; Or R8, R9 and the C atoms to which they are connected together form a 3-7 heterocyclic ring; R 10 Select from the following group: 1) Cyano, C1-C5 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, C3-C 10 Cycloalkyl, substituted or unsubstituted 5-12 membered aromatic ring, substituted or unsubstituted 3-12 membered heterocyclic ring; 2) Wherein Q1, Q2, Q3, Q4, Q5 are each independently selected from: CH, N or CR 11 ; Each R 11 Each is independently selected from the following group: halogen, cyano, hydroxyl, amino, nitro, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, C3-C8 cycloalkyl; R2 is selected from the following group: H, C1-C3 alkyl, When B is selected from the following group: NH, O, CO, CH2; wherein each U and W are independently selected from the following group: N or CH; each m, p, m', p' are independently: 0, 1, 2 or 3; Linker is: in, R L1 , R L2 , R L3 , R L4 and R L5 are the same or different and are each independently selected from the following substituted or unsubstituted groups: chemical bond, CH2, CHD, CD2, C=O, O, NH, SO, SO2, P=O, NHCO, NHSO2, OCH2, OCH2CH2, CH2OCH2, NHCH2, NMeCH2, NHCH2CH2, NMeCH2CH2, CH2NHCO, NHCOCH2, R L6 is a ring, and is optionally selected from the following structures: wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m are independently 0, 1 or 2; each U and W are independently selected from the following group: N or CH; p L1 、p L2 、p L3 、p L4 、p L5 and p L6 are each independently selected from 0, 1, 2, 3, 4, 5, or 6; or When B is Wherein each m, p, m', p' is independently: 0, 1, 2 or 3; Linker is: in, R L1 , R L2 , R L3 , R L4 , R L5 and R L6 are the same or different and are each independently selected from the following substituted or unsubstituted groups: chemical bond, CH2, CHD, CD2, C=O, O, NH, SO, SO2, P=O, NHCO, NHSO2, OCH2, OCH2CH2, CH2OCH2, NHCH2, NMeCH2, NHCH2CH2, NMeCH2CH2, CH2NHCO, NHCOCH2, wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m are independently 0, 1 or 2; each U and W are independently selected from the group consisting of N or CH; p L1 、p L2 、p L3 、p L4 、p L5 and p L6 Each is independently selected from 0, 1, 2, 3, 4, 5, or 6.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: B is selected from the following group: NH, O, CO; wherein each U and W are independently selected from the following group: N or CH; and each m, p, m', p' are independently 0, 1, 2 or 3.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: Ring A is selected from the group consisting of: Wherein, W is selected from the following group: CH, N; R' is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, amino, C1-C5 alkyl, halogenated C1-C5 alkyl, C1-C5 alkoxy, halogenated C1-C5 alkoxy, and C3-C8 cycloalkyl.
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: The D, E, F, and G are CH and CR6; wherein R6 is selected from the following group: halogen.
5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: When B is selected from the following group: NH, O, CO; the Linker is selected from the following group: And when B is When the linker is selected from the group consisting of chemical bonds, 6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: It has the structure shown in formula (II): Wherein, B is selected from: wherein each U and W are independently selected from the following group: N or CH; each m, p, m', p' are independently 0, 1, 2 or 3; R' is optionally selected from: hydrogen, halogen, cyano, hydroxyl, amino; R 11 , R6 is optionally selected from: hydrogen, halogen; X, Y are independently selected from: CH, N or CR3; Wherein, R3 is selected from: halogen, cyano, hydroxyl, amino; Z is optionally selected from: CH2 or CO.
7. A compound having the structure of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, or a prodrug molecule thereof: in, Z is selected from the group consisting of CH2 or CO; V is selected from the following group: X, Y are selected from the following group: N, CH or CR3; Wherein, R3 is selected from the following group: halogen, cyano, hydroxyl, amino, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, halogenated C1-C3 alkoxy, C3-C8 cycloalkyl, or 3-8 membered heterocyclyl; B is selected from the following group: NH, O, CO, CH2; wherein each U and W are independently selected from the following group: N or CH; each m and p are independently: 0, 1 or 2; Ring A is selected from the group consisting of: M and T are each independently selected from the following group: N, CR4; I, J, and K are each independently selected from the group consisting of N, O, S, CR4, and NR4; R4 is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, amino, C1-C5 alkyl, halogenated C1-C5 alkyl, C1-C5 alkoxy, halogenated C1-C5 alkoxy, C3-C8 cycloalkyl, -CH2R5, -(CH2)2R5, -(CH2)3R5 or 3-8 membered heterocyclyl; R5 is selected from the group consisting of cyano, hydroxy, amino, C3-C8 cycloalkyl, or 3-8 membered heterocyclyl; D, E, F, G are each independently selected from the group consisting of CH, N, CR6; wherein R6 is selected from the group consisting of halogen, trifluoromethyl, hydroxy, cyano, amino, methyl, methoxy, trifluoromethoxy; R1 is selected from the group consisting of H, -NHR7, -OR7, -(C(R9)R8)R7; Where R7 is -R 10 、-CH2R 10 or -(CH2)2R 10 ; R8 and R9 are each independently selected from the following group: hydrogen, halogen, cyano, methyl, halomethyl, methoxy, halomethoxy, ethyl, haloethyl, ethoxy, haloethoxy, hydroxyl, amino, 3-8 membered heterocycle containing 1, 2 or 3 heteroatoms, wherein the heteroatoms are selected from O, S or N; Or R8, R9 and the C atoms to which they are connected together form a 3-7 heterocyclic ring; R 10 Select from the following group: 1) Cyano, C1-C5 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, C3-C 10 Cycloalkyl, substituted or unsubstituted 5-12 membered aromatic ring, substituted or unsubstituted 3-12 membered heterocyclic ring; 2) Wherein Q1, Q2, Q3, Q4, Q5 are each independently selected from: CH, N or CR 11 ; Each R 11 Each is independently selected from the following group: halogen, cyano, hydroxyl, amino, nitro, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, C3-C8 cycloalkyl; R2 is selected from the following group: H, C1-C3 alkyl, Linker is: Among them, R L1 -R L6 are the same or different and are each independently selected from the following groups, substituted or unsubstituted: bond, CH2, CHD, CD2, C=O, O, NH, SO, SO2, P=O, NHCO, NHSO2, OCH2, OCH2CH2, CH2OCH2, NHCH2, NMeCH2, NHCH2CH2, NMeCH2CH2, CH2NHCO, NHCOCH2, wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m are independently 0, 1 or 2; each U and W are independently selected from the following group: N or CH The substitution refers to substitution by one or more groups selected from the group consisting of hydrogen, deuterium, C1-C 18 Alkyl, deuterated C1- C 18 Alkyl, halogenated C1-C 18 Alkyl, halogenated C1-C 18 Alkyl hydroxyl, C3-C 20 Cycloalkyl, C1-C 18 Alkoxy, deuterated C1-C 18 Alkoxy, halogenated C1-C 18 Alkoxy, C6-C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclic group, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide or urea; Each p L1 -p L6 Independently selected from 0, 1, 2, 3, 4, 5, or 6.
8. The compound according to claim 1 or 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: V is selected from the following group:
9. The compound according to claim 1 or 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: X and Y are each independently selected from the following group: N, CH or CR3; Wherein, R3 is selected from the following group: halogen, cyano, hydroxyl, amino, C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy, halogenated C1-C3 alkoxy.
10. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: B is selected from the following group: NH, O, CO; wherein each U and W are independently selected from the following group: N or CH; and each m and p are independently 0 or 1.
11. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: Ring A is selected from the group consisting of: Wherein, T is selected from the following group: CH, N.
12. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: R4 is selected from the following group: hydrogen, halogen, cyano, hydroxyl, amino, C1-C5 alkyl, halogenated C1-C5 alkyl, C1-C5 alkoxy, halogenated C1-C5 alkoxy, C3-C8 cycloalkyl, -CH2R5, -(CH2)2R5, -(CH2)3R5 or 3-8 membered heterocyclyl.
13. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: The D, E, F and G are CH.
14. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: The R1 is -NHR7; Wherein, R7 is -CH2R 10 ; R 10 The definition is as stated in claim 7. In another preferred embodiment, the R 10 Selected from the following group: cyano, C1-C5 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, C3-C 10 Cycloalkyl, 4-7 membered heterocyclic group, C6-C 10 Aryl; wherein the aryl is replaced by one or more CR 11 Replacement; R 11 The definition is as stated in claim 7.
15. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: Linker is selected from the following group: wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m is independently 0, 1 or 2; each U and W is independently selected from the group consisting of N or CH. In another preferred embodiment, Linker is selected from the following group: wherein each n is independently 0, 1, 2, 3, 4, 5 or 6; each r and m is independently 0, 1 or 2; each U and W is independently selected from the group consisting of N or CH.
16. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: It has a structure shown in formula (II) or formula (III): Wherein, U and W are independently selected from: CH or N; X, Y are independently selected from: CH, N or CR3; Z is selected from: CH2 or CO; n, m are independently selected from: 0 or 1.
17. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: The compound is selected from the group consisting of:
18. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug molecule thereof, characterized in that: The compound is selected from the group consisting of:
19. A pharmaceutical composition, characterized in that Include (1) A compound as claimed in any one of claims 1 to 18, or a pharmaceutically acceptable salt, a stereoisomer thereof, or a prodrug molecule thereof as an active ingredient; and Optional (2) a pharmaceutically acceptable carrier.
20. Use of the compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule thereof, or the pharmaceutical composition according to claim 19, characterized in that: Used to prepare CDK12 / 13 protein kinase degrader.
21. Use of the compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule thereof, or the pharmaceutical composition according to claim 19, characterized in that: Used for preparing drugs for preventing and / or treating diseases mediated by CDK12 / 13 serine / threonine protein kinase.
22. The use according to claim 21, characterized in that The disease mediated by CDK12 / 13 serine / threonine protein kinase is selected from the following group: prostate cancer, breast cancer, uterine cancer, ovarian cancer, non-small cell lung cancer, small cell lung cancer, Ewing sarcoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, liver cancer, skin cancer, epithelial cell carcinoma, gastrointestinal stromal tumor, leukemia, histiocytic lymphoma, nasopharyngeal carcinoma, head and neck tumors, colon cancer, rectal cancer, glioma.
